Informes Periódicos de Orphanet

serie Medicamentos Huérfanos

Enero 2020

Listados de medicamentos para enfermedades raras en Europa*

**Autorización de comercialización de la Comunidad Europea mediante el procedimiento centralizado*

www.orpha.net www.orphadata.org

Liberté • Égalité • Fraternité
RÉPUBLIQUE FRANÇAISE
MINISTÈRE DES AFFAIRES SOCIALES ET DE LA SANTÉ

Inserm
La science pour la santé
From science to health

AFMTÉLÉTHON
INNOVER POUR GUERIR

Co-funded by the Health Programme of the European Union

Índice general

PARTE 1:

Listado de medicamentos huérfanos en Europa con designación huérfana europea y autorización de comercialización europea* 3

Índice 3

Metodología 3

Clasificación por nombre comercial 5

Anexo 1: Medicamentos huérfanos retirados del Registro comunitario de medicamentos huérfanos 21

Anexo 2: Medicamentos huérfanos retirados de su uso en la Unión Europea 30

Clasificación por fecha de la AC en orden decreciente 32

Clasificación por categoría ATC 34

Clasificación por titular de la AC 36

PARTE 2 :

Listado de productos medicinales para enfermedades raras en Europa con autorización de comercialización europea* sin designación huérfana en Europa 38

Índice 38

Metodología 38

Clasificación por nombre comercial 39

Clasificación por fecha de la AC en orden decreciente 87

Clasificación por categoría ATC 89

Clasificación por el titular de la AC 91

Para cualquier pregunta o comentario, por favor contacte con: *contact.orphanet@inserm.fr*

PARTE 1:

Listado de medicamentos huérfanos en Europa con designación huérfana europea y autorización de comercialización europea*

Índice

Listado de medicamentos huérfanos en Europa con designación huérfana europea y autorización de comercialización europea* 3

Metodología 3

Clasificación por nombre comercial 5

Anexo 1: Medicamentos huérfanos retirados del Registro comunitario de medicamentos huérfanos 21

Anexo 2: Medicamentos huérfanos retirados de su uso en la Unión Europea 30

Clasificación por fecha de la AC en orden decreciente 32

Clasificación por categoría ATC 34

Clasificación por titular de la AC 36

Metodología

En esta parte del documento se ofrece un listado de todos los medicamentos huérfanos que, hasta la fecha indicada en el documento, han recibido una autorización de comercialización (AC) europea. Estos medicamentos pueden estar accesibles a partir de ahora en algunos países europeos, aunque no necesariamente en todos. En realidad, la accesibilidad de un medicamento huérfano concreto en un determinado país depende de la estrategia del laboratorio y de la decisión tomada por parte de las autoridades sanitarias nacionales respecto al reembolso.

Los medicamentos huérfanos en Europa son aquellos fármacos a los que se les ha concedido una designación huérfana europea (de acuerdo con la regulación (EC) No 141/2000), y a los que se les ha concedido también una autorización de comercialización europea y, si es aplicable, una evaluación positiva de un beneficio significativo.

Este listado de medicamentos huérfanos en Europa, con designación huérfana y autorización de comercialización europea, se obtiene cruzando el listado de medicamentos que han recibido una designación huérfana (http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm) con el listado de medicamentos que han recibido una autorización de comercialización (http://ec.europa.eu/health/documents/community-register/html/ alfregister.htm). Ambos están disponibles en el sitio web de la Dirección General de Sanidad y Seguridad Alimentaria (DG SANTE) de la Comisión Europea.

Una primera clasificación por nombre comercial ofrece el nombre de la sustancia activa, la indicación de la autorización de comercialización (AC), y la fecha y el titular de la AC.

Le siguen dos tablas anexas que ofrecen:

- una tabla de medicamentos huérfanos retirados del Registro comunitario de medicamentos huérfanos

**Autorización de comercialización de la Comunidad Europea por procedimiento centralizado*

(consulte el Anexo 1 – « Medicamentos huérfanos retirados del Registro comunitario de medicamentos huérfanos »; sus indicaciones están detalladas en la Parte II, "Listado de productos medicinales para enfermedades raras en Europa con autorización de comercialización europea sin designación huérfana en Europa");

- una tabla de medicamentos retirados de su uso en la Unión Europea (consulte el Anexo 2 – Medicamentos huérfanos retirados de su uso en la Unión Europea). Más información en www.ema.europa.eu.

Tres listados adicionales proponen otras clasificaciones por:

- fecha de la AC en orden descendiente,

- categoría ATC,

- titular de la AC.

Para cada listado, los nombres comerciales se presentan en orden alfabético.

Puede encontrar información adicional de cada producto en la pestaña "Medicamentos huérfanos" del sitio web de Orphanet www.orphanet.es o en el sitio web de la EMA (Agencia Europea de Medicamentos) www.ema. europa.eu.

El listado de la EMA cubre todos los medicamentos autorizados en el mercado, no únicamente los medicamentos huérfanos. Los medicamentos huérfanos con designación huérfana europea están indicados con el logo 

La información oficial y actualizada sobre medicamentos huérfanos está disponible en el Registro comunitario de medicamentos huérfanos de uso humano: http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm

Clasificación por nombre comercial

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ADCETRIS	brentuximab vedotin	Indicated for adult patients with previously untreated CD30+ Stage IV **Hodgkin lymphoma** (**HL**) in combination with doxorubicin, vinblastine and dacarbazine (AVD). Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): -following autologous stem cell transplant (ASCT) or -following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment of adult patients with **CD30+ HL** at increased risk of relapse or progression following ASCT Treatment of adult patients with relapsed or refractory systemic **anaplastic large cell lymphoma** (**sALCL**). Treatment of adult patients with CD30+ **cutaneous T-cell lymphoma** (**CTCL**) after at least 1 prior systemic therapy.	25/10/2012	Takeda Pharma A/S
ADEMPAS	riociguat	Treatment of adult patients with WHO Functional Class (FC) II to III with inoperable **Chronic thromboembolic pulmonary hypertension** (**CTEPH**), persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. As monotherapy or in combination with endothelin receptor antagonists, for the treatment of adult patients with **pulmonary arterial hypertension (PAH)** with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including etiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.	27/03/2014	Bayer AG
ALOFISEL	darvadstrocel	Treatment of complex **perianal fistulas** in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.	23/03/2018	Takeda Pharma A/S
ALPROLIX	eftrenonacog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia B** (congenital factor IX deficiency). ALPROLIX can be used for all age groups.	12/05/2016	Swedish Orphan Biovitrum AB (publ)

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
AMGLIDIA	glibenclamide	Treatment of **neonatal diabetes mellitus**, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.	24/05/2018	Ammtek
BESPONSA	inotuzumab ozogamicin	As monotherapy for the treatment of adults with relapsed or refractory CD22-**positive B cell precursor acute lymphoblastic leukaemia** (**ALL**). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).	29/06/2017	Pfizer Europe MA EEIG
BLINCYTO	blinatumomab	Treatment of adults with Philadelphia chromosome negative relapsed or **refractory B -precursor acute lymphoblastic leukaemia** (**ALL**). As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.	23/11/2015	Amgen Europe B.V.
BRINEURA	cerliponase alfa	Treatment of **neuronal ceroid lipofuscinosis type 2** (**CLN2**) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.	30/05/2017	BioMarin International Limited
BRONCHITOL	mannitol	Treatment of **cystic fibrosis** (**CF**) in adults aged 18 years and above as an add-on therapy to best standard of care.	13/04/2012	Pharmaxis Europe Limited
CABLIVI	caplacizumab	Treatment of adults experiencing an episode of **acquired thrombotic thrombocytopenic purpura** (**aTTP**), in conjunction with plasma exchange and immunosuppression.	30/08/2018	Ablynx NV
CARBAGLU	carglumic acid	Treatment of **hyperammonaemia** due to - **isovaleric acidaemia**, - **methymalonic acidaemia**, - **propionic acidaemia.**	01/06/2011	Recordati Rare Diseases
CERDELGA	eliglustat	Long-term treatment of adult patients with **Gaucher disease type 1 (GD1)**, who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs)	19/01/2015	Genzyme Europe B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CHENODEOXYCHOLIC ACID LEADIANT (previously CHENODEOXYCHOLIC ACID SIGMA-TAU)	chenodeoxycholic acid	Treatment of **inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency** (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults.	10/04/2017	Leadiant GmbH
COAGADEX	human coagulation factor X	Treatment and prophylaxis of bleeding episodes and for perioperative management in patients with **hereditary factor X deficiency**.	16/03/2016	BPL Bioproducts Laboratory GmbH
COMETRIQ	cabozantinib	Treatment of adult patients with progressive, unresectable locally advanced or metastatic **medullary thyroid carcinoma**. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.	21/03/2014	IPSEN Pharma
CRESEMBA	isavuconazole	In adults for the treatment of: - **invasive aspergillosis** - **mucormycosis** in patients for whom amphotericin B is inappropriate	15/10/2015	Basilea Pharmaceutica Deutschland GmbH
CRYSVITA	burosumab	Treatment of **X-linked hypophosphataemia** with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.	19/02/2018	Kyowa Kirin Holdings B.V.
CYSTADROPS	mercaptamine hydrochloride	Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with **cystinosis**.	19/01/2017	Recordati Rare Diseases
DACOGEN	decitabine	Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary **acute myeloid leukaemia** (**AML**), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.	20/09/2012	Janssen-Cilag International N.V.
DARZALEX	daratumumab	In combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed **multiple myeloma** who are ineligible for autologous stem cell transplant. In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progre ssion on the last therapy.	20/05/2016	Janssen-Cilag International N.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
DEFITELIO	defibrotide	Treatment of **severe hepatic veno-occlusive disease** (**VOD**) also known as **sinusoidal obstructive syndrome** (**SOS**) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.	18/10/2013	Gentium SRL
DELTYBA	delamanib	Used as part of an appropriate combination regimen for **pulmonary multi-drug resistant tuberculosis** (**MDR-TB**) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	28/04/2014	Otsuka Novel Products GmbH
EPIDYOLEX	Cannabidiol	As adjunctive therapy of seizures associated with **Lennox Gastaut syndrome** (**LGS**) or **Dravet syndrome** (**DS**), in conjunction with clobazam, for patients 2 years of age and older.	19/09/2019	GW Pharma (International) B.V.
ESBRIET	pirfenidone	In adults for the treatment of mild to moderate **Idiopathic Pulmonary Fibrosis** (**IPF**).	28/02/2011	Roche Registration GmbH
FARYDAK	panobinostat lactate anhydrous	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory **multiple myeloma** who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	28/08/2015	Secura Bio Limited
FIRAZYR	icatibant acetate	Symptomatic treatment of acute attacks of **hereditary angioedema** (**HAE**) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.	11/07/2008	Shire Pharmaceuticals Ireland Limited
FIRDAPSE (previously ZENAS)	amifampridine	Symptomatic treatment of **Lambert-Eaton myasthenic syndrome** (**LEMS**) in adults.	23/12/2009	BioMarin International Limited
GALAFOLD	migalastat	Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of **Fabry disease** (**α-galactosidase A deficiency**) and who have an amenable mutation.	26/05/2016	Amicus Therapeutics Europe Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
GAZYVARO	obinutuzumab	In combination with chlorambucil, treatment of adult patients with previously untreated **chronic lymphocytic leukaemia** (**CLL**) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. In combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response is indicated for the treatment of patients with previously untreated advanced **follicular lymphoma**. In combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.	23/07/2014	Roche Registration GmbH
GRANUPAS (previously PARA-AMINOSALICYLIC ACID LUCANE)	para-aminosali- cylic acid	Indicated for use as part of an appropriate combination regimen for **multi-drug resistant tuberculosis** in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	07/04/2014	Eurocept International B.V.
HETLIOZ	tasimelteon	Treatment of **Non-24-Hour Sleep-Wake Disorder (Non-24)** in totally blind adults.	03/07/2015	Vanda Pharmaceuticals Germany GmbH
HOLOCLAR	ex vivo expanded autologous human corneal epithelial cells containing stem cells	Treatment of adult patients with moderate to severe **limbal stem cell deficiency** (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns. A minimum of 1 - 2 mm^2 of undamaged limbus is required for biopsy.	17/02/2015	Chiesi Farmaceutici SpA
ICLUSIG	ponatinib	Indicated in adult patients with chronic phase, accelerated phase, or blast phase **chronic myeloid leukaemia** (**CML**) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Indicated in adult patients with **Philadelphia chromosome positive acute lymphoblastic leukaemia** (**Ph+ ALL**) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	01/07/2013	Incyte Biosciences Distribution B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
IDELVION	albutrepenonacog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia B** (**congenital factor IX deficiency**). IDELVION can be used for all age groups.	11/05/2016	CSL Behring GmbH
IMBRUVICA	ibrutinib	As a single agent for the treatment of adult patients with relapsed or refractory **mantle cell lymphoma** (**MCL**). As a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated **chronic lymphocytic leukaemia** (**CLL**). As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy. As a single agent for the treatment of adult patients with **Waldenström's macroglobulinaemia** (**WM**) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	21/10/2014	Janssen-Cilag International N.V.
IMNOVID (previously POMALIDOMIDE CELGENE)	pomalidomide	In combination with bortezomib and dexamethasone indicated in the treatment of adult patients with **multiple myeloma** who have received at least one prior treatment regimen including lenalidomide. In combination with dexamethasone, in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.	05/08/2013	Celgene Europe B.V.
ISTURISA	osilodrostat	Treatment of **endogenous Cushing's syndrome** in adults	13/01/2020	Novartis Europharm Limited
JORVEZA	budesonide	Treatment of **eosinophilic esophagitis** (**EoE**) in adults (older than 18 years of age).	08/01/2018	Dr. Falk Pharma GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
KALYDECO	ivacaftor	KALYDECO tablets: Treatment of patients with **cystic fibrosis** (**CF**) aged 6 years and older and weighing 25kg or more who have one of the following gating (class III) mutations in the *CFTR* gene:*G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R*. Treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an *R117H* mutation in the *CFTR* gene. In a combination regimen with tezacaftor 100 mg/ivacaftor 150 mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the *F508del* mutation or who are heterozygous for the *F508del* mutation and have one of the following mutations in the *CFTR* gene: *P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.* KALYDECO granules: Treatment of children with cystic fibrosis (CF) aged 12 months and older and weighing 7 kg to less than 25 kg who have one of the following gating (class III) mutations in the *CFTR* gene: *G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.*	23/07/2012	Vertex Pharmaceuticals (Ireland) Limited
KANUMA	sebelipase alfa	Long-term enzyme replacement therapy (ERT) in patients of all ages with **lysosomal acid lipase** (**LAL**) **deficiency**	28/08/2015	Alexion Europe SAS
KETOCONAZOLE HRA	ketoconazole	Treatment of **endogenous Cushing's syndrome** in adults and adolescents above the age of 12 years.	19/11/2014	HRA Pharma Rare Diseases
KOLBAM (previously CHOLIC ACID FGK)	cholic acid	Treatment of **inborn errors in primary bile acid synthesis** due to **sterol 27-hydroxylase** (presenting ascerebrotendinous xanthomatosis, CTX) **deficiency, 2- (or α-) methylacyl-CoA racemase** (**AMACR**) **deficiency** or **cholesterol 7α-hydroxylase** (**CYP7A1**) **deficiency** in infants, children and adolescents aged 1 month to 18 years and adults.	08/04/2014	Retrophin Europe Ltd
KUVAN	sapropterin dihydrochloride	Treatment of **hyperphenylalaninaemia** (**HPA**) in adult and paediatric patients of all ages with **phenylketonuria** (**PKU**) who have been shown to be responsive to such treatment. Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with **tetrahydrobiopterin** (**BH4**) **deficiency** who have been shown to be responsive to such treatment.	02/12/2008	Biomarin International Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
KYMRIAH	tisagenlecleucel	Treatment of: - Paediatric and young adult patients up to 25 years of age with **B-cell acute lymphoblastic leukaemia** (**ALL**) that is refractory, in relapse post-transplant or in second or later relapse. - Adult patients with relapsed or refractory **diffuse large B-cell lymphoma** (**DLBCL**) after two or more lines of systemic therapy.	22/08/2018	Novartis Europharm Limited
KYPROLIS	carfilzomib	In combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with **multiple myeloma** who have received at least one prior therapy.	19/11/2015	Amgen Europe B.V.
LAMZEDE	velmanase alfa	Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate **alpha mannosidosis**.	23/03/2018	Chiesi Farmaceutici S.p.A.
LEDAGA	chlormethine	Topical treatment of **mycosis fungoides-type cutaneous T-cell lymphoma** (**MF-type CTCL**) in adult patients.	03/03/2017	Helsinn Birex Pharmaceuticals Ltd.
LUTATHERA	lutetium (177Lu) oxodotreotide	Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive **gastroenteropancreatic neuroendocrine tumours** (**GEP NET**s) in adults.	26/09/2017	Advanced Accelerator Applications
LUXTURNA	voretigene neparvovec	Treatment of adult and paediatric patients with vision loss due to **inherited retinal dystrophy** caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.	22/11/2018	Novartis Europharm Limited
MEPSEVII	vestronidase alfa	Treatment of non-neurological manifestations of **Mucopolysaccharidosis VII** (**MPS VII**; **Sly syndrome**).	22/08/2018	Ultragenyx Germany GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
MOZOBIL	plerixafor	Adult patients: Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with **lymphoma** or **multiple myeloma** whose cells mobilise poorly Paediatric patients (1to less than 18years): Mozobil is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma orsolid malignant tumours,either: -pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield,or -who previously failed to collect sufficient haematopoietic stem cells	31/07/2009	Genzyme Europe B.V.
MYALEPTA	metreleptin	As an adjunct to diet as a replacement therapy to treat the complications of **leptin deficiency** in lipodystrophy (**LD**) patients: - with confirmed **congenital generalised LD** (**Berardinelli-Seip syndrome**) or **acquired generalised LD** (**Lawrence syndrome**) in adults and children 2 years of age and above - with confirmed **familial partial LD** or **acquired partial LD** (**Barraquer-Simons syndrome**), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.	29/07/2018	Aegerion Pharmaceuticals B.V.
MYLOTARG	gemtuzumab ozogamicin	In combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive **acute myeloid leukaemia** (**AML**), except acute promyelocytic leukaemia (APL).	19/04/2018	Pfizer Europe MA EEIG
NAMUSCLA	mexiletine hcl	Symptomatic treatment of myotonia in adult patients with **non-dystrophic myotonic disorders**.	18/12/2018	Lupin Europe GmbH
NATPAR	parathyroid hormone	Indicated as adjunctive treatment of adult patients with chronic **hypoparathyroidism** who cannot be adequately controlled with standard therapy alone.	24/04/2017	Shire Pharmaceuticals Ireland Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
NEXAVAR	sorafenib tosylate	Treatment of patients with progressive, locally advanced or metastatic, **differentiated (papillary/ follicular/Hürthle cell) thyroid carcinoma**, refractory to radioactive iodine.	19/07/2006	Bayer AG
NEXOBRID	concentrate of proteolytic en- zymes enriched in bromelain	Removal of eschar in adults with **deep partial-** and **full-thickness thermal burns.**	18/12/2012	Mediwound Germany Gmbh
NINLARO	ixazomib	In combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with **multiple myeloma** who have received at least one prior therapy.	21/11/2016	Takeda Pharma A/S
OCALIVA	obeticholic acid	Treatment of **primary biliary cholangitis** (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.	12/12/2016	Intercept Pharma International Ltd
OFEV	nintedanib	Treatment in adults of **Idiopathic Pulmonary Fibrosis** (**IPF**).	15/01/2015	Boehringer Ingelheim International GmbH
ONIVYDE	irinotecan hydrochloride trihydrate	Treatment of metastatic **adenocarcinoma of the pancreas**, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy.	14/10/2016	Les Laboratoires Servier
ONPATTRO	Patisiran sodium	Treatment of **hereditary transthyretin - mediated amyloidosis** (**hATTR amyloidosis**) in adult patients with stage 1 or stage 2 polyneuropathy.	26/08/2018	Alnylam Netherlands B.V.
OPSUMIT	macitentan	Used as monotherapy or in combination, for the long-term treatment of **pulmonary arterial hypertension** (**PAH**) in adult patients of WHO Functional Class (FC) II to III. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.	20/12/2013	Janssen-Cilag International N.V.
ORPHACOL	cholic acid	Treatment of **inborn errors in primary bile acid synthesis due to 3beta-hydroxy-delta5-C27- steroid oxidoreductase deficiency or delta4-3-oxosteroid-5beta-reductase deficiency** in infants, children and adolescents aged 1 month to 18 years and adults.	12/09/2013	Laboratoires CTRS
OXERVATE	cenegermin	Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) **neurotrophic keratitis** in adults.	06/07/2017	Dompe farmaceutici s.p.a.
PALYNZIQ	pegvaliase	Treatment of patients with **phenylketonuria** (**PKU**) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options.	03/05/2019	BioMarin International Limited
PLENADREN	hydrocortisone	Treatment of **adrenal insufficiency** in adults.	03/11/2011	Shire Services BVBA

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
POLIVY	polatuzumab vedotin	In combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory **diffuse large B-cell lymphoma** (**DLBCL**) who are not candidates for haematopoietic stem cell transplant.	20/01/2020	Roche Registration GmbH
POTELIGEO	mogamulizumab	Treatment of adult patients with **mycosis fungoides** (**MF**) or **Sézary syndrome** (**SS**) who have received at least one prior systemic therapy.	22/11/2018	Kyowa Kirin Holdings B.V.
PREVYMIS	letermovir	Prophylaxis of **cytomegalovirus** (**CMV**) **reactivation and disease** in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). Consideration should be given to official guidance on the appropriate use of antiviral agents.	08/01/2018	Merck Sharp & Dohme B.V.
PROCYSBI	mercaptamine	Treatment of proven **nephropathic cystinosis**. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	06/09/2013	Chiesi Farmaceutici SpA
QARZIBA (previously DINUTUXIMAB BETA APEIRON)	dinutuximab beta	Treatment of high-risk **neuroblastoma** in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Dinutuximab beta Apeiron should be combined with interleukin-2 (IL-2).	08/05/2017	EUSA Pharma (Netherlands) B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
RAVICTI	glycerol phenylbutyrate	Indicated for use as adjunctive therapy for chronic management of patients with **urea cycle disorders** (**UCDs**) including: **deficiencies of carbamoyl phosphate-synthase-I** (**CPS**) -**ornithine carbamoyltransferase** (**OTC**) - **argininosuccinate synthetase** (**ASS**), - **argininosuccinate lyase** (**ASL**) - **arginase I** (**ARG**) - **ornithine translocase deficiency hyperornithinaemia -hyperammonaemia homocitrullinuria syndrome** (**HHH**) Who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).	27/11/2015	Immedica Pharma AB
RAXONE	idebenone	Treatment of visual impairment in adolescent and adult patients with **Leber's Hereditary Optic Neuropathy** (**LHON**).	08/09/2015	Santhera Pharmaceuticals (Deutschland) GmbH
REVESTIVE	teduglutide	Treatment of patients aged 1 year and above with **Short Bowel Syndrome**. Patients should be stable following a period of intestinal adaptation after surgery.	30/08/2012	Shire Pharmaceuticals Ireland Limited
RYDAPT	midostaurin	In combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed **acute myeloid leukaemia** (**AML**) who are FLT3 mutation positive. As monotherapy for the treatment of adult patients with **aggressive systemic mastocytosis** (**ASM**), **systemic mastocytosis with associated haematological neoplasm** (**SM AHN**), or **mast cell leukaemia** (**MCL**).	18/09/2017	Novartis Europharm Limited
SCENESSE	afamelanotide	Prevention of phototoxicity in adult patients with **erythropoietic protoporphyria** (**EPP**)	22/12/2014	Clinuvel Europe Limited
SIGNIFOR	pasireotide	Treatment of adult patients with **Cushing's disease** for whom surgery is not an option or for whom surgery has failed. Treatment of adult patients with **acromegaly** for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.	24/04/2012	Novartis Europharm Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
SIRTURO	bedaquiline	Used as part of an appropriate combination regimen for **pulmonary multidrug-resistant tuberculosis** (**MDR-TB**) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	05/03/2014	Janssen-Cilag International N.V.
SOLIRIS	eculizumab	In adults and children for the treatment of **atypical haemolytic uraemic syndrome** (**aHUS**). In adults for the treatment of: - refractory **generalized myasthenia gravis** (**gMG**) in patients who are anti-acetylcholine receptor (AChR) antibody-positive. - **neuromyelitis optica spectrum disorder** (**NMOSD**) in patients who are anti-quaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.	20/06/2007	Alexion Europe SAS
SOMAKIT TOC	edotreotide	After radiolabelling with gallium (^{68}Ga) chloride solution, the solution of gallium (^{68}Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated **gastro-enteropancreatic neuroendocrine tumours** (**GEP-NET**) for localizing primary tumours and their metastases.	08/12/2016	Advanced Accelerator Applications
SPINRAZA	nusinersen sodium	Treatment of **5q Spinal Muscular Atrophy**.	30/05/2017	Biogen Netherlands B.V.
STRENSIQ	asfotase alfa	Long-term enzyme replacement therapy in patients with **paediatric-onset hypophosphatasia** to treat the bone manifestations of the disease.	28/08/2015	Alexion Europe SAS
STRIMVELIS	autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells	Treatment of patients with **severe combined immunodeficiency due to adenosine deaminase deficiency** (**ADA-SCID**), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.	26/05/2016	Orchard Therapeutics (Netherlands) B.V.
SYLVANT	siltuximab	Treatment of adult patients with **multicentric Castleman's disease** (**MCD**) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	22/05/2014	EUSA Pharma (Netherlands) B.V

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
SYMKEVI	tezacaftor/ivacaftor	In a combination regimen with ivacaftor 150 mg tablets for the treatment of patients with **cystic fibrosis** (**CF**) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene: *P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.*	31/10/2018	Vertex Pharmaceuticals (Ireland) Limited
TAKHZYRO	lanadelumab	For routine prevention of recurrent attacks of **hereditary angioedema** (**HAE**) in patients aged 12 years and older.	22/11/2018	Shire Pharmaceuticals Ireland Limited
TEGSEDI	inotersen	Treatment of stage 1 or stage 2 polyneuropathy in adult patients with **hereditary transthyretin amyloidosis** (**hATTR**)	10/07/2018	Akcea Therapeutics Ireland Limited.
TEPADINA	thiotepa	In combination with other chemotherapy medicinal products: 1) with or without total body irradiation (TBI), as conditioning treatment prior to **allogeneic or autologous haematopoietic progenitor cell transplantation** (**HPCT**) in **haematological diseases** in adult and paediatric patients; 2) when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.	15/03/2010	Adienne S.r.l.
TOBI PODHALER	tobramycin	Suppressive therapy of chronic pulmonary infection due to *Pseudomonas aeruginosa* in adults and children aged 6 years and older with **cystic fibrosis.** Consideration should be given to official guidance on the appropriate use of antibacterial agents.	20/07/2011	Mylan IRE Healthcare Limited
TRANSLARNA	ataluren	Treatment of **Duchenne muscular dystrophy** resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.	31/07/2014	PTC Therapeutics International Ltd
VERKAZIA	ciclosporin	Treatment of severe **vernal keratoconjunctivitis** (**VKC**) in children from 4 years of age and adolescents.	06/07/2018	Santen Oy
VIMIZIM	elosulfase alfa	Treatment of **mucopolysaccharidosis, type IVA** (**Morquio A Syndrome, MPS IVA**) in patients of all ages.	28/04/2014	BioMarin International Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VOTUBIA	everolimus	Treatment of adult patients with **renal angiomyolipoma** associated with **tuberous sclerosis complex** (**TSC**) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume. Treatment of patients with **subependymal giant cell astrocytoma** (**SEGA**) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.	02/09/2011	Novartis Europharm Ltd
VPRIV	velaglucerase alfa	Long-term enzyme replacement therapy (ERT) in patients with **type 1 Gaucher disease.**	26/08/2010	Shire Pharmaceuticals Ireland Ltd
VYNDAQEL	tafamidis	Treatment of **transthyretin amyloidosis** in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.	16/11/2011	Pfizer Europe MA EEIG
VYXEOS	daunorubicin hydrochloride / cytarabine	Treatment of adults with newly diagnosed, **therapy-related acute myeloid leukaemia** (**t-AML**) **or AML with myelodysplasia-related changes** (**AML-MRC**).	22/08/2018	Jazz Pharmaceuticals Ireland Limited
WAKIX	pitolisant	Treatment in adults of **narcolepsy with or without cataplexy**.	31/03/2016	Bioprojet Pharma
WAYLIVRA	volanesorsen	Indicated as an adjunct to diet in adult patients with genetically confirmed **familial chylomicronemia syndrome** (**FCS**) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	03/05/2019	Akcea Therapeutics Ireland Limited
XALUPRINE (previously MERCAP-TOPURINE NOVA)	mercaptopurine	Treatment of **acute lymphoblastic leukaemia** (**ALL**) in adults, adolescents and children.	09/03/2012	Nova Laboratories Ireland Limited
XERMELO	telotristat	Treatment of **carcinoid syndrome** diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.	18/09/2017	Ipsen Pharma
XOSPATA	gilteritinib fumarate	As monotherapy for the treatment of adult patients who have relapsed or refractory **acute myeloid leukaemia** (**AML**) with a FLT3 mutation	24/10/2019	Astellas Pharma Europe B.V.
YESCARTA	axicabtagene ciloleucel	Treatment of adult patients with relapsed or refractory **diffuse large B-cell lymphoma** (**DLBCL**) and **primary mediastinal large B-cell lymphoma** (**PMBCL**), after two or more lines of systemic therapy.	22/08/2018	Kite Pharma EU B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ZEJULA	niraparib	As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade **serous epithelial ovarian**, **fallopian tube**, or **primary peritoneal cancer** who are in response (complete or partial) to platinum based chemotherapy.	16/11/2017	TESARO Bio Netherlands B.V.
ZYNTEGLO	Autologous CD34+ cells encoding βA-T87Q-globin gene	Treatment of patients 12 years and older with **transfusion-dependent β-thalassaemia** (**TDT**) who do not have a β^0/β^0genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.	29/05/2019	Bluebird bio (Netherlands) B.V.

Anexo 1: Medicamentos huérfanos retirados del Registro comunitario de medicamentos huérfanos

Las indicaciones de los productos listados en la siguiente tabla están detallados en la Parte II "Listado de productos medicinales para enfermedades raras en Europa con autorización de comercialización europea sin designación huérfana en Europa"

Algunos productos han perdido la designación huérfana para alguna de sus indicaciones, pero no para todas. En estos casos, las indicaciones para las que han perdido la designación huérfana se mencionan más abajo.

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
AFINITOR	everolimus	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 5 June 2007.	05/08/2009	08/07/2011
ALDURAZYME	laronidase	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 14 February 2001.	12/06/2003	12/06/2013
ATRIANCE	nelarabine	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 16 June 2005.	22/08/2007	24/08/2017
BAVENCIO	avelumab	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 14 December 2015.	18/09/2017	07/10/2019
BOSULIF	bosutinib	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 4 August 2010.	27/03/2013	15/03/2018
BUSILVEX	busulfan	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 29 December 2000	11/07/2003	11/07/2013
CARBAGLU	carglumic acid	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition: - Treatment of ***N-acetylglutamate synthetase (NAGS) deficiency***. It was originally designated an orphan medicine for this indication on 18 October 2000.	28/01/2003	28/01/2013
CAYSTON	aztreonam	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 21 June 2004.	21/09/2009	23/10/2019

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
CEPLENE	histamine dihydrochloride	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 11 April 2005.	09/10/2008	09/10/2018
CYRAMZA	ramucirumab	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 6 July 2012.	23/12/2014	27/01/2016
CYSTADANE	betaine anhydrous	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 9 July 2001.	15/02/2007	19/02/2017
DIACOMIT	stiripentol	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 5 December 2001.	04/01/2007	09/01/2017
ELAPRASE	idursulfase	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 11 December 2001.	08/01/2007	10/01/2017
EVOLTRA	clofarabine	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 7 February 2002.	31/05/2006	31/05/2016
EXJADE	deferasirox	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 13 mars 2002	01/09/2006	01/09/2016
FABRAZYME	agalsidase beta	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 8 August 2000.	07/08/2001	07/08/2011
GLIOLAN	5-aminole-vulinic acid hydrochloride	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 13 November 2002.	07/09/2007	12/09/2017

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
GLIVEC	imatinib mesilate	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following conditions: - Treatment of ***chronic myeloid leukaemia*** (it was designated an orphan medicine on 14/02/2001). It was withdrawn from the Community register of orphan medicinal products on April 2012 **on request of the sponsor** for the following conditions: - Treatment of malignant ***gastrointestinal stromal tumours*** (it was designated an orphan medicine on 20/11/2001) - Treatment of ***dermatofibrosarcoma protuberans*** (it was designated an orphan medicine on 26/08/2005); - Treatment of ***acute lymphoblastic leukaemia*** (it was designated an orphan medicine on 26/08/2005); - Treatment of ***chronic eosinophilic leukaemia*** and the ***hypereosinophilic syndrome*** (it was designated an orphan medicine on 28/10/2005) - Treatment of ***myelodysplastic / myeloproliferative diseases*** (it was designated an orphan medicine on 23/12/2005)	12/11/2001 27/05/2002 18/09/2006 18/09/2006 01/12/2006 01/12/2006	12/11/2011 16/04/2012
ILARIS	canakinumab	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 20 March 2007.	27/10/2009	01/12/2010
INCRELEX	mecasermin	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 22 May 2006.	03/08/2007	07/08/2017
INOVELON	rufinamide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity+ 2 years for an agreed paediatric investigation plan (PIP)** granted on 13 January 2017. It was originally designated an orphan medicine on 20 October 2004.	16/01/2007	18/01/2019

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
JAKAVI	ruxolitinib	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor** for the following conditions: -Treatment of ***polycythaemia vera*** (it was designated an orphan medicine on 19/02/2014) -Treatment of chronic ***idiopathic myelofibrosis*** (it was designated an orphan medicine on 07/11/2008) -Treatment of ***myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia*** (it was designated an orphan medicine on 03/04/2009).	28/08/2012	20/02/2015
LENVIMA	lenvatinib	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 26 April 2013.	28/05/2015	01/08/2018
LITAK	cladribine	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 18 September 2001.	19/04/2004	19/04/2014
LYNPARZA	olaparib	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 6 December 2007.	16/12/2014	16/03/2018
LYSODREN	mitotane	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 12 June 2002.	30/04/2004	30/04/2014
MEPACT	mifamurtide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 21 June 2004.	06/03/2009	23/03/2019
MYOZYME	alglucosidase alfa	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 22 February 2001.	31/03/2006	31/03/2016
NAGLAZYME	galsulfase	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 22 February 2001.	26/01/2006	26/01/2016

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
NEXAVAR	sorafenib tosylate	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following conditions: -Treatment of ***renal cell carcinoma*** (it was designated an orphan medicine on 29/07/2004) - Treatment of ***hepatocellular carcinoma*** (it was designated an orphan medicine on 11/04/2006).	19/07/2006 29/10/2007	22/07/2016 01/11/2017
NPLATE	romiplostim	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 27 May 2005.	04/02/2009	06/02/2019
ORFADIN	nitisinone	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 29 December 2000.	24/02/2005	24/02/2015
PEDEA	ibuprofen	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 14 February 2001.	02/08/2004	02/08/2014
PEYONA (previously NYMUSA)	caffeine citrate	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 18 February 2003.	02/07/2009	06/07/2019
PRIALT	ziconotide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 9 July 2001.	24/02/2005	24/02/2015
REPLAGAL	agalsidase alfa	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 8 August 2000.	07/08/2001	07/08/2011
REVATIO	Sildenafil citrate	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 17 December 2003.	04/11/2005	04/11/2015

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
REVLIMID	lenalidomide	This product is no longer an orphan medicine. It was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition: - Treatment of ***multiple myeloma***. It was originally designated an orphan medicine for this indication on 12 December 2003 It was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor** for the following conditions: - Treatment of **myelodysplastic syndromes.** It was originally designated an orphan medicine for this indication on 8 March 2004 - Treatment of ***mantle cell lymphoma***. It was originally designated an orphan medicine for this indication on 27 October 2011.	14/06/2007 13/06/2013 08/07/2016	19/06/2017 12/12/2019 12/12/2019
REVOLADE	eltrombopag	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 3 August 2007.	15/03/2010	01/01/2012
RUBRACA	rucaparib	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 10 October 2012.	24/05/2018	4/12/2018
SAVENE	dexrazoxane	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 19 september 2001	02/08/2006	02/08/2016
SIKLOS	hydroxycarba-mide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 9 July 2003.	29/06/2007	05/07/2017
SOLIRIS	eculizumab	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity + 2 years for an agreed paediatric investigation plan (PIP)** for the following indication: Treatment of ***paroxysmal nocturnal haemoglobinuria***. It was originally designated an orphan medicine on 17 October 2003.	20/06/2007	22/06/2019
SOMAVERT	pegvisomant	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 14 February 2001.	15/11/2002	15/11/2012

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
SPRYCEL	dasatinib	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 23 December 2005	20/11/2006	22/11/2016
SUTENT	sunitinib malate	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 10 March 2005.	15/01/2007	23/07/2008
TASIGNA	nilotinib	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 22 May 2006.	21/11/2007	17/11/2019
THALIDOMIDE CELGENE (previously THALIDOMIDE PHARMION)	thalidomide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 20 November 2001.	16/04/2008	18/04/2018
TORISEL	temsirolimus	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition:. - First-line treatment of adult patients with advanced ***renal cell carcinoma (RCC)*** who have at least three of six prognostic risk factors. (It was originally designated an orphan medicine on 6/04/2006). - Treatment of adult patients with relapsed and/ or refractory ***mantle cell lymphoma (MCL)***. (It was originally designated an orphan medicine on 6/11/2006)	19/11/2007 21/08/2009	21/11/2017 25/08/2019
TRACLEER	bosentan monohydrate	This product is no longer an orphan medicine. It was withdrawn from the Community register of orphan medicinal products **on request of the sponsor** for the following condition: -Treatment of ***systemic sclerosis*** (it was designated an orphan medicine on 17/03/2003) It was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition: - Treatment of ***pulmonary arterial hypertension*** and chronic ***thromboembolic pulmonary hypertension*** (it was designated an orphan medicine on 14/02/2001)	11/06/2007 17/05/2002	04/04/2014 17/05/2012

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
TRISENOX	arsenic trioxide	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 18 October 2000.	07/03/2002	07/03/2012
VENCLYXTO	venetoclax	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 6 December 2012.	05/12/2016	12/10/2018
VENTAVIS	iloprost	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 29 December 2000.	18/09/2003	18/09/2013
VIDAZA	azacitidine	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 6 February 2002 for ***myelodysplastic syndromes*** and on 29 November 2007 for ***acute myeloid leukaemia***.	17/12/2008	22/12/2018
VOLIBRIS	ambrisentan	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 11 April 2005.	21/04/2008	24/04/2018
WILZIN	zinc acetate dihydrate	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity**. It was originally designated an orphan medicine on 31 July 2001.	18/10/2004	18/10/2014
XAGRID	anagrelide hydrochloride	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity+ 2 years for an agreed paediatric investigation plan (PIP)**. It was originally designated an orphan medicine on 29 December 2000.	16/11/2004	18/11/2016
XYREM	sodium oxybate	This product was withdrawn from the Community Register of designated orphan medicinal products **on request of the sponsor**. It was originally designated an orphan medicine on 3 February 2003.	18/10/2005	11/01/2010

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS	MARKETING AUTHORIZATION DATE	ORPHAN DESIGNATION WITHDRAWAL DATE
YONDELIS	trabectedin	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition:		
		- Treatment of ***soft tissue sarcoma*** . It was originally designated an orphan medicine for this indication on 30 May 2001.	17/09/2007	21/09/2017
NEW		- Treatment of ***ovarian cancer***. It was originally designated an orphan medicine for this indication on 17 October 2003.	28/10/2009	31/10/2019
ZAVESCA	miglustat	This product was withdrawn from the Community register of orphan medicinal products **at the end of the 10-year period of market exclusivity** for the following condition:	21/11/2002	21/11/2012
		- Treatment of ***type 1 Gaucher disease***. It was originally designated an orphan medicine for this indication on 18 October 2000.		
		- Treatment of progressive neurological manifestations in adult patients and paediatric patients with ***Niemann-Pick type C*** disease.	28/01/2009	28/01/2019

Anexo 2: Medicamentos huérfanos retirados de su uso en la Unión Europea

Mas información: www.ema.europa.eu

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION (MA) INDICATION	MA DATE / MA HOLDER	MA WITHDRAWN DATE
ARZERRA	ofatumumab	In combination with chlorambucil or bendamustine, for the treatment of patients with **chronic lymphocytic leukaemia (CLL)** who have not received prior therapy and who are not eligible for fludarabine-based therapy. In combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL. Treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.	19/04/2010 Novartis Europharm Limited	25/02/2019
GLYBERA	alipogene tiparvovec	For adult patients diagnosed with **familial lipoprotein lipase deficiency** (**LPLD**) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.	25/10/2012 uniQure biopharma B.V.	29/10/2017
LARTRUVO	olaratumab	In combination with doxorubicin for the treatment of adult patients with advanced **soft tissue sarcoma** who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin	09/11/2016 Eli Lilly Nederland B.V	23/07/2019
ONSENAL	celecoxib	Reduction of the number of adenomatous intestinal polyps in **familial adenomatous polyposis** (**FAP**), as an adjunct to surgery and further endoscopic surveillance.	17/10/2003 Pfizer Ltd	28/03/2011
PHOTOBARR	porfimer sodium (for use with photodynamic therapy)	Ablation of high-grade dysplasia (HGD) in patients with **Barrett's oesophagus.**	25/03/2004 Pinnacle Biologics B.V.	20/04/2012
RILONACEPT REGENERON (previously ARCALYST)	rilonacept	Treatment of **Cryopyrin-Associated Periodic Syndromes** (**CAPS**) with severe symptoms, including **Familial Cold Autoinflammatory Syndrome** (**FCAS**) and **Muckle-Wells Syndrome** (**MWS**), in adults and children aged 12 years and older.	23/10/2009 Regeneron UK Ltd	24/10/2012
THELIN	sitaxentan sodium	Treatment of patients with **pulmonary arterial hypertension** classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.	10/08/2006 Pfizer Ltd	06/01/2011
UNITUXIN	dinutuximab	Treatment of high-risk **neuroblastoma** in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is	14/08/2015 United Therapeutics Europe Ltd	20/03/2017

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION (MA) INDICATION	MA DATE / MA HOLDER	MA WITHDRAWN DATE
		administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.		
NEW ZALMOXIS	allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)	Indicated as adjunctive treatment in haploidentical **haematopoietic stem cell transplantation** (**HSCT**) of adult patients with **high-risk haematological malignancies**.	18/08/2016 MolMed SpA	11/10/2019

Clasificación por fecha de la AC en orden decreciente

2020
ISTURISA
POLIVY
2019
EPIDYOLEX
PALYNZIQ
WAYLIVRA
XOSPATA
ZYNTEGLO
2018
ALOFISEL
AMGLIDIA
CABLIVI
CRYSVITA
JORVEZA
KYMRIAH
LAMZEDE
LUXTURNA
MEPSEVII
MYALEPTA
MYLOTARG
NAMUSCLA
ONPATTRO
POTELIGEO
PREVYMIS
SYMKEVI
TAKHZYRO
TEGSEDI
VERKAZIA
VYXEOS
YESCARTA
2017

BESPONSA
BRINEURA
CHENODEOXYCHOLIC ACID LEADIANT
CYSTADROPS
LEDAGA
LUTATHERA
NATPAR
OXERVATE
QARZIBA
RYDAPT
SPINRAZA
XERMELO
ZEJULA
2016
ALPROLIX
COAGADEX
DARZALEX
GALAFOLD
IDELVION
NINLARO
OCALIVA
ONIVYDE
SOMAKIT TOC
STRIMVELIS
WAKIX
2015
BLINCYTO
CERDELGA
CRESEMBA
FARYDAK
HETLIOZ
HOLOCLAR

KANUMA
KYPROLIS
OFEV
RAVICTI
RAXONE
STRENSIQ
2014
ADEMPAS
COMETRIQ
DELTYBA
GAZYVARO
GRANUPAS
IMBRUVICA
KETOCONAZOLE HRA
KOLBAM
SCENESSE
SIRTURO
SYLVANT
TRANSLARNA
VIMIZIM
2013
DEFITELIO
ICLUSIG
IMNOVID
OPSUMIT
ORPHACOL
PROCYSBI
2012
ADCETRIS
BRONCHITOL
DACOGEN
KALYDECO

NEXOBRID
REVESTIVE
SIGNIFOR
XALUPRINE
2011
CARBAGLU
ESBRIET
PLENADREN
TOBI PODHALER
VOTUBIA
VYNDAQEL
2010
TEPADINA
VPRIV
2009
FIRDAPSE
MOZOBIL
2008
FIRAZYR
KUVAN
2007
SOLIRIS
2006
NEXAVAR


Número de medicamentos huérfanos en Europa con designación huérfana europea y autorización de comercialización europea por fecha de la AC
1
1
2
2
2
6
8
6
13
12
11
13
21
5
2
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020

Clasificación por categoría ATC

A- ALIMENTARY TRACT AND METABOLISM
AMGLIDIA
BRINEURA
CARBAGLU
CERDELGA
CHENODEOXYCHOLIC ACID LEADIANT
GALAFOLD
JORVEZA
KANUMA
KOLBAM
KUVAN
LAMZEDE
MEPSEVII
MYALEPTA
OCALIVA
ORPHACOL
PALYNZIQ
PROCYSBI
RAVICTI
REVESTIVE
STRENSIQ
VIMIZIM
VPRIV
XERMELO
B- BLOOD AND BLOOD FORMING
ALPROLIX
CABLIVI
COAGADEX
DEFITELIO
IDELVION
TAKHZYRO
ZYNTEGLO
C-CARDIOVASCULAR SYSTEM
ADEMPAS
FIRAZYR
NAMUSCLA
OPSUMIT
D- DERMATOLOGICALS
NEXOBRID
SCENESSE
H- SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
ISTURISA
NATPAR
PLENADREN
SIGNIFOR
J- GENERAL ANTIINFECTIVES FOR SYSTEMIC USE
CRESEMBA
DELTYBA
GRANUPAS
KETOCONAZOLE
PREVYMIS
SIRTURO
TOBI PODHALER
L- ANTINEOPLASTIC AND IMMUNOMODULATING
ADCETRIS
ALOFISEL
BESPONSA
BLINCYTO
COMETRIQ
DACOGEN
DARZALEX
ESBRIET
FARYDAK
GAZYVARO
ICLUSIG
IMBRUVICA
IMNOVID
KYMRIAH
KYPROLIS
LEDAGA
MOZOBIL
MYLOTARG
NEXAVAR
NINLARO
OFEV
ONIVYDE
POLIVY
POTELIGEO
QARZIBA
RYDAPT
SOLIRIS
STRIMVELIS
SYLVANT
TEPADINA
VOTUBIA
VYXEOS
XALUPRINE
XOSPATA
YESCARTA
ZEJULA
M- MUSCULO-SKELETAL SYSTEM
CRYSVITA
TRANSLARNA
N- NERVOUS SYSTEM
EPIDYOLEX
FIRDAPSE
HETLIOZ
ONPATTRO
RAXONE
SPINRAZA
VYNDAQEL
WAKIX
R- RESPIRATORY
BRONCHITOL
KALYDECO
SYMKEVI
S- SENSORY ORGANS
CYSTADROPS
HOLOCLAR
OXERVATE
VERKAZIA
V- VARIOUS
LUTATHERA
SOMAKIT TOC
PENDING
LUXTURNA
TEGSEDI
WAYLIVRA

Número de medicamentos huérfanos en Europa con designación huérfana europea y autorización de comercialización europea por categoría ATC



Clasificación por titular de la AC

ABLYNX N.V.
CABLIVI
ADIENNE SRL
TEPADINA
ADVANCED ACCELERATOR APPLICATIONS
LUTATHERA
SOMAKIT TOC
AEGERION PHARMACEUTICALS B.V.
MYALEPTA
AKCEA THERAPEUTICS IRELAND LTD.
TEGSEDI
WAYLIVRA
ALEXION EUROPE SAS
KANUMA
SOLIRIS
STRENSIQ
ALNYLAM NETHERLANDS B.V.
ONPATTRO
AMGEN EUROPE B.V.
BLINCYTO
KYPROLIS
AMICUS THERAPEUTICS EUROPE LIMITED
GALAFOLD
AMMTEK
AMGLIDIA
ASTELLAS PHARMA EUROPE B.V.
XOSPATA
BASILEA PHARMACEUTICA DEUTSCHLAND GMBH
CRESEMBA
BAYER AG
ADEMPAS
NEXAVAR
BIOGEN NETHERLANDS B.V.
SPINRAZA
BIOMARIN INTERNATIONAL LIMITED
BRINEURA
FIRDAPSE
KUVAN
PALYNZIQ
VIMIZIM
BIOPROJET PHARMA
WAKIX
BLUEBIRD BIO (NETHERLANDS) B.V.
ZYNTEGLO
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
OFEV
BPL BIOPRODUCTS LABORATORY GMBH
COAGADEX
CELGENE EUROPE B.V.
IMNOVID
CHIESI FARMACEUTICI SPA
HOLOCLAR
LAMZEDE
PROCYSBI
CLINUVEL EUROPE LIMITED
SCENESSE
CSL BEHRING GMBH
IDELVION
DOMPE FARMACEUTICI S.P.A.
OXERVATE
DR. FALK PHARMA GMBH
JORVEZA
EUROCEPT INTERNATIONAL B.V.
GRANUPAS
EUSA PHARMA (NETHERLANDS) B.V.
QARZIBA
SYLVANT
GENTIUM SRL
DEFITELIO
GENZYME EUROPE B.V.
CERDELGA
MOZOBIL
GW PHARMA (INTERNATIONAL) B.V.
EPIDYOLEX
HELSINN BIREX PHARMACEUTICALS LTD.
LEDAGA
HRA PHARMA HRA PHARMA RARE DISEASES
KETOCONAZOLE HRA
IMMEDICA PHARMA AB
RAVICTI
INCYTE BIOSCIENCES DISTRIBUTION B.V.
ICLUSIG
INTERCEPT PHARMA INTERNATIONAL LTD
OCALIVA
IPSEN PHARMA
COMETRIQ
XERMELO
JANSSEN-CILAG INTERNATIONAL NV
DACOGEN
DARZALEX
IMBRUVICA
OPSUMIT
SIRTURO
JAZZ PHARMACEUTICALS IRELAND LTD
VYXEOS
KITE PHARMA EU B.V.
YESCARTA
KYOWA KIRIN HOLDINGS B.V.
CRYSVITA
POTELIGEO
LABORATOIRES CTRS
ORPHACOL
LEADIANT GmbH
CHENODEOXYCHOLIC ACID LEADIANT
LES LABORATOIRES SERVIER
ONIVYDE
LUPIN EUROPE GmbH
NAMUSCLA
MEDIWOUND GERMANY GMBH
NEXOBRID
MERCK SHARP & DOHME B.V.
PREVYMIS
MYLAN IRE HEALTHCARE LIMITED
TOBI PODHALER
NOVA LABORATORIES IRELAND LIMITED
XALUPRINE
NOVARTIS EUROPHARM LTD
ISTURISA
KYMRIAH
LUXTURNA
RYDAPT
SIGNIFOR
VOTUBIA
ORCHARD THERAPEUTICS (NETHERLANDS) B.V.
STRIMVELIS
OTSUKA NOVEL PRODUCTS GMBH
DELTYBA
PFIZER EUROPE MA EEIG
BESPONSA
MYLOTARG
VYNDAQEL
PHARMAXIS EUROPE LIMITED
BRONCHITOL
PTC THERAPEUTICS INTERNATIONAL LTD
TRANSLARNA
RECORDATI RARE DISEASES
CARBAGLU
CYSTADROPS
RETROPHIN EUROPE LTD
KOLBAM
ROCHE REGISTRATION GMBH
ESBRIET
GAZYVARO
POLIVY
SANTEN OY
VERKAZIA
SANTHERA PHARMACEUTICALS (DEUTSCHLAND) GMBH
RAXONE
SECURA BIO LIMITED
FARYDAK
SHIRE PHARMACEUTICALS IRELAND LTD
FIRAZYR
NATPAR
REVESTIVE
TAKHZYRO
VPRIV
SHIRE SERVICES BVBA
PLENADREN
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
ALPROLIX
TAKEDA PHARMA A/S.
ADCETRIS
ALOFISEL
NINLARO
TESARO BIO NETHERLANDS B.V.
ZEJULA
ULTRAGENYX GERMANY GMBH
MEPSEVII
VANDA PHARMACEUTICALS GERMANY GMBH

HETLIOZ	PHARMACEUTICALS (IRELAND) LIMITED	KALYDECO
VERTEX		SYMKEVI

PARTE 2 :

Listado de productos medicinales para enfermedades raras en Europa con autorización de comercialización europea* sin designación huérfana en Europa

Índice

Listado de productos medicinales para enfermedades raras en Europa con autorización de comercialización europea* sin designación huérfana en Europa **38**

Metodología *38*

Clasificación por nombre comercial *39*

Clasificación por fecha de la AC en orden decreciente *87*

Clasificación por categoría ATC *89*

Clasificación por el titular de la AC *91*

Metodología

En esta parte del documento se ofrece un listado de todos los medicamentos para enfermedades raras que han recibido una autorización de comercialización (AC) europea para una o más indicaciones de uso para una enfermedad rara, pero que no han recibido una designación huérfana europea o cuya designación ha sido retirada.

A estos fármacos se les puede haber concedido, o no, una designación huérfana en otras áreas geográficas del mundo. Aparecen en el listado de medicamentos de la Dirección DG SANTE a los que se les ha concedido una autorización de comercialización: http://ec.europa.eu/health/documents/community-register/html/alfregister.htm

Una primera clasificación por nombre comercial ofrece el nombre de la sustancia activa, la indicación rara de la autorización de comercialización (AC), y la fecha y el titular de la AC.

Tres listados adicionales proponen otras clasificaciones por:

- fecha de la AC en orden descendiente,

- categoría ATC,

- titular de la AC.

Para cada listado, los nombres comerciales se presentan en orden alfabético.

Puede encontrar información adicional de cada producto en la pestaña “Medicamentos huérfanos” del sitio web de Orphanet www.orphanet.es o en el sitio web de la EMA (Agencia Europea de Medicamentos) http://www.ema.europa.eu.

**Autorización de comercialización de la Comunidad Europea por procedimiento centralizado*

Clasificación por nombre comercial

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ABRAXANE	paclitaxel	In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic **adenocarcinoma of the pancreas**.	11/01/2008	Celgene Europe B.V.
ABSEAMED	epoetin alfa	Treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary **myelodysplastic syndromes** (**MDS**) who have low serum erythropoietin (<200 mU/ml).(Indication extension)	27/08/2007	Medice Arzneimittel Pütter GmbH Co. KG
ACCOFIL	filgrastim	In patients, children or adults with severe **congenital**, **cyclic**, or **idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	18/09/2014	ACCORD HEALTHCARE S.L.U.
ADCIRCA	tadalafil	In adults for the treatment of **pulmonary arterial hypertension** (**PAH**) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	01/10/2008	Eli Lilly Nederland B.V.
ADVATE	octocog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**). It is indicated in all age groups.	02/03/2004	Baxter AG
ADYNOVI	rurioctocog alfa pegol	Treatment and prophylaxis of bleeding in patients 12 years and above with **haemophilia A** (congenital factor VIII deficiency).	08/01/2018	Baxalta Innovations GmbH
AFINITOR	everolimus	Treatment of unresectable or metastatic, well- or moderately-differentiated **neuroendocrine tumours of pancreatic origin** in adults with progressive disease. Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional **neuroendocrine tumours of gastrointestinal** or **lung origin** in adults with progressive disease Treatment of patients with advanced **renal cell carcinoma**, whose disease has progressed on or after treatment with VEGF-targeted therapy.	03/08/2009	Novartis Europharm Ltd
AFSTYLA	lonoctocog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (congenital factor VIII deficiency).	04/01/2017	CSL Behring GmbH
ALDURAZYME	laronidase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of **Mucopolysaccharidosis I** (**MPS I**; a **[alpha]-L-iduronidase deficiency**) to treat the non-neurological manifestations of the disease.	10/06/2003	Genzyme Europe B.V.
ALIMTA	pemetrexed	Treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	20/09/2004	Eli Lilly Nederland B.V.
ALKINDI	hydrocortisone	Replacement therapy of **adrenal insufficiency** in infants, children and adolescents (from birth to < 18 years old).	09/02/2018	Diurnal Europe B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
AMBRISENTAN MYLAN	ambrisentan	Treatment of **pulmonary arterial hypertension** (**PAH**) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in **idiopathic PAH** (**IPAH**) and in **PAH associated with connective tissue disease**.	20/06/2019	Mylan S.A.S
AMGEVITA	Adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). AMGEVITA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids,in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.	22/03/2017	Amgen Europe B.V.
AMMONAPS	sodium phenylbutyrate	Adjunctive therapy in the chronic management of **urea cycle disorders**, involving **deficiencies of carbamyl phosphate synthetase**, **ornithine transcarbamylase**, or **argininosuccinate synthetase**. It is indicated in all patients with *neonatal-onset* presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with *late-onset* disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.	08/12/1999	Immedica Pharma AB
ANAGRELIDE MYLAN	anagrelide hydrochloride	Indicated for the reduction of elevated platelet counts in at risk **essential thrombocythaemia** (**ET**) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk essential thrombocythaemia patient is defined by one or more of the following features: • > 60 years of age or • A platelet count > 1,000 x 109/l or an history of thrombo-haemorrhagic events.	15/02/2018	Mylan S.A.S.
ARMISARTE (previously PEMETREXED ACTAVIS)	pemetrexed	In combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	18/01/2016	Actavis Group PTC ehf

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ARSENIC TRIOXIDE ACCORD	arsenic trioxide	For induction of remission, and consolidation in adult patients with: - Newly diagnosed low-to-intermediate risk **acute promyelocytic leukaemia** (**APL**) (white blood cell count, ≤ 10 x 103/µl) in combination with all-trans-retinoic acid (ATRA) - Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.	14/11/2019	Accord Healthcare S.L.U.
ATRIANCE	nelarabine	Treatment of patients with **T-cell acute lymphoblastic leukaemia** (**T-ALL**) and **T-cell lymphoblastic lymphoma** (**T-LBL**) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.	22/08/2007	Novartis Europharm Ltd
AVASTIN	bevacizumab	In combination with interferon alfa-2a it is indicated for first line treatment of adult patients with advanced and/or metastatic **renal cell cancer**. In combination with carboplatin and paclitaxel, it is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) **epithelial ovarian, fallopian tube**, or **primary peritoneal cancer**. In combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin it is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	12/01/2005	Roche Registration GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
AZACITIDINE CELGENE	azacitidine	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: - intermediate-2 and high-risk **myelodysplastic syndromes** (**MDS**) according to the International Prognostic Scoring System (IPSS), - **chronic myelomonocytic leukaemia** (**CMML**) with 10-29% marrow blasts without myeloproliferative disorder, - **acute myeloid leukaemia** (**AML**) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, - AML with >30% marrow blasts according to the WHO classification.	02/08/2019	Celgene Europe BV
BAVENCIO	avelumab	As monotherapy for the treatment of adult patients with metastatic **Merkel cell carcinoma** (**MCC**). In combination with axitinib is indicated for the first-line treatment of adult patients with advanced **renal cell carcinoma** (**RCC**).	18/09/2017	Merck Europe B.V.
BEMFOLA	follitropin alfa	In adult men: stimulation of spermatogenesis in men who have **congenital** or **acquired hypogonadotropic hypogonadism** with concomitant human chorionic gonadotropin (hCG) therapy.	27/03/2014	Gedeon Richter Plc.
BENEFIX	nonacog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia B** (**congenital factor IX deficiency**).	27/08/1997	Pfizer Europe MA EEIG
BESREMI	ropeginterferon alfa-2b	Indicated as monotherapy in adults for the treatment of **polycythaemia vera** without symptomatic splenomegaly.	15/02/2019	AOP Orphan Pharmaceuticals AG
BINOCRIT	epoetin alfa	Treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary **myelodysplastic syndromes** (**MDS**) who have low serum erythropoietin (<200 mU/ml). (Indication extension)	27/08/2007	Sandoz GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
BLITZIMA	rituximab	Treatment of previously untreated patients with stage III-IV **follicular lymphoma** in combination with chemotherapy. As maintenance therapy indicated for the treatment of follicular lymphoma patients responding to induction therapy. As monotherapy indicated for the treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy. Treatment of patients with CD20 positive **diffuse large B cell non-Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with chemotherapy for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Blitzima or patients refractory to previous Blitzima plus chemotherapy.	13/07/2017	Celltrion Healthcare Hungary Kft.
BORTEZOMIB ACCORD	bortezomib	As monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone for the treatment of adult patients with progressive **multiple myeloma** who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated **mantle cell lymphoma** who are unsuitable for haematopoietic stem cell transplantation.	20/07/2015	Accord Healthcare S.L.U.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
BORTEZOMIB FRESENIUS KABI	bortezomib	As monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone for the treatment of adult patients with progressive **multiple myeloma** who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated **mantle cell lymphoma** who are unsuitable for haematopoietic stem cell transplantation.	14/11/2019	Fresenius Kabi Deutschland GmbH
BORTEZOMIB HOSPIRA	bortezomib	As monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive **multiple myeloma** who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated **mantle cell lymphoma** who are unsuitable for haematopoietic stem cell transplantation.	22/07/2016	Pfizer Europe MA EEIG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
BORTEZOMIB SUN	bortezomib	As monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive **multiple myeloma** who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated **mantle cell lymphoma** who are unsuitable for haematopoietic stem cell transplantation.	22/07/2016	SUN Pharmaceutical Industries (Europe) B.V.
BOSULIF	bosutinib	Treatment of adult patients with: - newly diagnosed chronic phase (CP) **Philadelphia chromosome-positive chronic myelogenous leukaemia** (**Ph+ CML**). - CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	27/03/2013	Pfizer Europe MA EEIG
BUCCOLAM	midazolam	Treatment of prolonged, acute, convulsive **seizures in infants, toddlers, children and adolescents** (from 3 months to < 18 years).Buccolam must only be used by parents/carers where the patient has been **diagnosed to have epilepsy**. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.	05/09/2011	Shire Services BVBA
BUSILVEX	busulfan	Followed by cyclophosphamide (BuCy2), conditioning treatment prior to conventional **haematopoietic progenitor cell transplantation** in adult patients when the combination is considered the best available option. Following fludarabine (FB), conditioning treatment prior to haematopoietic progenitor cell transplantation in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen. Followed by cyclophosphamide (BuCy4) or melphalan (BuMel), conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.	09/07/2003	Pierre Fabre Médicament

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CABOMETYX	cabozantinib	Treatment of advanced **renal cell carcinoma** (**RCC**): - in treatment-naïve adults with intermediate or poor risk - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. As monotherapy for the treatment of **hepatocellular carcinoma** (**HCC**) in adults who have previously been treated with sorafenib.	09/09/2016	Ipsen Pharma
CAELYX	doxorubicin hydrochloride (pegylated liposomal)	Treatment of **advanced ovarian cancer** in women who have failed a first-line platinum-based chemotherapy regimen. In combination with bortezomib for the treatment of progressive **multiple myeloma** in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. Treatment of AIDS-related **Kaposi's sarcoma** (**KS**) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. Used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).	21/06/1996	Janssen-Cilag International N.V.
CANCIDAS (previously CASPOFUNGIN MSD)	caspofungin	Treatment of **invasive candidiasis** in adult or paediatric patients. Treatment of **invasive aspergillosis** in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.	24/10/2001	Merck Sharp & Dohme B.V.
CAPRELSA	vandetanib	Treatment of aggressive and symptomatic **medullary thyroid cancer** (**MTC**) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.	17/02/2012	Genzyme Europe B.V.
CARBAGLU	carglumic acid	Treatment of **hyperammonaemia due to N-acetylglutamate synthase (NAGS) primary deficiency**	28/01/2003	Recordati Rare Diseases

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CARMUSTINE OBVIUS	carmustine	As a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): - Brain tumours (**glioblastoma**, **Brain-stem gliomas**, **medulloblastoma**, **astrocytoma** and **ependymoma**), brain metastases - Secondary therapy in **non-Hodgkin's lymphoma** and **Hodgkin's disease**.	18/07/2018	Obvius Investment B.V.
CAYSTON	aztreonam	Suppressive therapy of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with **cystic fibrosis** (**CF**) aged 6 years and older.	21/09/2009	Gilead Sciences Ireland UC
CEPLENE	histamine dihydrochloride	Maintainance therapy for adult patients with **acute myeloid leukaemia** in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.	09/10/2008	Noventia Pharma Srl
CEPROTIN	human protein c	In purpura fulminans and coumarin-induced skin necrosis in patients with severe **congenital protein C deficiency.** Short-term prophylaxis in patients with severe congenital protein C deficiency if one or more of the following conditions are met: - surgery or invasive therapy is imminent, - while initiating coumarin therapy, - when coumarin therapy alone is not sufficient, - when coumarin therapy is not feasible.	16/07/2001	Baxter AG
CEREZYME	imiglucerase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of **non-neuronopathic** (**Type 1**) or **chronic neuronopathic** (**Type 3**) **Gaucher disease** and who exhibit clinically significant. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: -Anaemia after exclusion of other causes, such as iron deficiency -Thrombocytopenia -Bone disease after exclusion of other causes such as Vitamin D deficiency -Hepatomegaly or splenomegaly	17/11/1997	Genzyme Europe B.V.
CINRYZE	C1 inhibitor(human)	Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with **hereditary angioedema (HAE)**. Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.	15/06/2011	Shire Services BVBA

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
COLOBREATHE	colistimethate sodium	Management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with **cystic fibrosis** (**CF**) aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	13/02/2012	Teva B.V.
CUFENCE	trientine dihydrochloride	Treatment of **Wilson's disease** in patients intolerant to D-Penicillamine therapy, in adults, adolescents and children aged 5 years or older.	25/07/2019	Univar BV
CUPRIOR	trientine	Treatment of **Wilson's disease** in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.	05/09/2017	GMP-Orphan SA
CYRAMZA	ramucirumab	As monotherapy for the treatment of adult patients with advanced or unresectable **hepatocellular carcinoma** who have a serum alpha fetoprotein (AFP) of ≥400 ng/ml and who have been previously treated with sorafenib.	19/12/2014	Eli Lilly Nederland B.V.
CYSTADANE	betaine anhydrous	Adjunctive treatment of **homocystinuria**, involving **deficiencies** or **defects in cystathionine beta- synthase** (**CBS**), **5,10-methylene-tetrahydrofolate reductase** (**MTHFR**), **cobalamin cofactor metabolism (cbl)**. Cystadane should be used as supplement to other therapies such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a specific diet.	15/02/2007	Recordati Rare Diseases
CYSTAGON	mercaptamine bitartrate	Treatment of proven **nephropathic cystinosis.** Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells)of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	23/06/1997	Recordati Rare Diseases
DEFERASIROX MYLAN	deferasirox	Treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with **beta thalassaemia major** aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years, - in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older, - in adult and paediatric patients with other anaemias aged 2 years and older. Treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion dependent thalassaemia syndromes aged 10 years and older.	26/09/2019	Mylan S.A.S

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
DEFERIPRONE LIPOMED	deferiprone	As monotherapy for the treatment of iron overload in patients with **thalassaemia major** when current chelation therapy is contraindicated or inadequate. Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.	19/09/2018	Lipomed GmbH
DENGVAXIA	dengue tetravalent vaccine (live, attenuated)	Prevention of **dengue disease** caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 9 to 45 years of age with prior dengue virus infection and living in endemic areas.	12/12/2018	Sanofi Pasteur
DIACOMIT	stiripentol	Used in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with **severe myoclonic epilepsy in infancy** (**SMEI, Dravet's syndrome**) whose seizures are not adequately controlled with clobazam and valproate.	04/01/2007	Biocodex
DUKORAL	vibrio cholerae and recombinant cholera toxinb-subunit	Indicated for active immunisation against disease caused by ***Vibrio cholerae*** **serogroup O1** in adults and children from 2 years of age who will be visiting endemic/epidemic areas. The use of Dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions. Dukoral should not replace standard protective measures. In the event of diarrhoea measures of rehydration should be instituted.	28/04/2004	Valneva Sweden AB
ELAPRASE	idursulfase	Long-term treatment of patients with **Hunter syndrome** (**Mucopolysaccharidosis II, MPS II**). Heterozygous females were not studied in the clinical trials.	08/01/2007	Shire Human Genetic Therapies AB
ELMIRON	pentosan polysulfate sodium	Treatment of **bladder pain syndrome** characterized by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.	02/06/2017	bene-Arzneimittel GmbH
ELOCTA	efmoroctocog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (congenital factor VIII deficiency). ELOCTA can be used for all age groups.	19/11/2015	Swedish Orphan Biovitrum AB (publ)

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
EMPLICITI	elotuzumab	In combination with lenalidomide and dexamethasone for the treatment of **multiple myeloma** in adult patients who have received at least one prior therapy. In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.	11/05/2016	Bristol-Myers Squibb Pharma EEIG
ENBREL	etanercept	Treatment of **polyarthritis** (rheumatoid-factorpositive or -negative) and extended **oligoarthritis** in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of **psoriatic arthritis in adolescents** from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of **enthesitis-related arthritis in adolescents** from the age of 12 years who have had an inadequate response to, or who have proved intolerant of conventional therapy. Enbrel has not been studied in children aged less than 2 years.	03/02/2000	Pfizer Europe MA EEIG
EPOETIN ALFA HEXAL	epoetin alfa	Treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary **myelodysplastic syndromes** (**MDS**) who have low serum erythropoietin (<200 mU/ml). (Indication extension)	27/08/2007	Hexal AG
ERBITUX	cetuximab	Treatment of patients with **squamous cell cancer of the head and neck** : - in combination with radiation therapy for locally advanced disease, - in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.	29/06/2004	Merck Europe B.V.
ERELZI	etanercept	Treatment of **polyarthritis** (rheumatoid factor positive or negative) and extended **oligoarthritis in children and adolescents** from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of **psoriatic arthritis in adolescents** from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of **enthesitis-related arthritis in adolescents** from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Etanercept has not been studied in children aged less than 2 years.	23/06/2017	Sandoz GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ERIVEDGE	vismodegib	Treatment of adult patients with symptomatic metastatic **basal cell carcinoma** Treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy	12/07/2013	Roche Registration GmbH
ERVEBO	Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live)	For active immunization of individuals 18 years of age or older to protect against **Ebola Virus Disease** (**EVD**) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.	11/11/2019	Merck Sharp & Dohme B.V.
ESPEROCT	turoctocog alfa pegol	Treatment and prophylaxis of bleeding in patients 12 years and above with **haemophilia A** (congenital factor VIII deficiency).	20/06/2019	Novo Nordisk A/S
EURARTESIM	piperaquine tetraphosphate/ dihydroartemi-sinin	Treatment of uncomplicated ***Plasmodium falciparum* malaria** in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.	27/10/2011	Alfasigma S.p.A
EVOLTRA	clofarabine	Treatment of **acute lymphoblastic leukaemia** (**ALL**) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.	29/05/2006	Genzyme Europe B.V.
EXJADE	deferasirox	Treatment of chronic iron overload due to frequent blood transfusions (≥7ml/kg/month of packed red blood cells) in patients with **beta thalassaemia major** aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy s contraindicated or inadequate in the following patient groups: -in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7ml/kg/month of packed red blood cells) aged 2 to 5 years, -in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7ml/kg/month of packed red blood cells)aged 2years and older, -in adult and paediatric patients with other anaemias aged 2 years and older. Treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with **non-transfusion dependent thalassaemia syndromes** aged 10years and older.	01/09/2006	Novartis Europharm Limited
FABRAZYME	agalsidase beta	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of **Fabry disease** (**alphagalactosidase A deficiency**).	03/08/2001	Genzyme Europe B.V.
FERRIPROX	deferiprone	Treatment of iron overload in patients with **thalassaemia major** when deferoxamine therapy is contraindicated or inadequate.	25/08/1999	Apotex B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
FILGRASTIM HEXAL	filgrastim	In patients, children or adults, with **severe congenital, cyclic,** or **idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/l, and a history of severe or recurrent infections. Long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	06/02/2009	Hexal AG
FLEBOGAMMA DIF	human normal immunoglobulin	Replacement therapy in adults, and children and adolescents (2-18 years) in: **- Primary immunodeficiency** (**PID**) syndromes with impaired antibody production. **- Hypogammaglobulinaemia** and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed. **- Hypogammaglobulinaemia** and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation. **- Hypogammaglobulinaemia** in patients after allogeneic haematopoietic stem cell transplantation (HSCT). Immunomodulation in adults, and children and adolescents (2-18 years) in - **Primary immune thrombocytopenia** (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. **- Guillain-Barré syndrome** **- Kawasaki disease** (in conjunction with acetylsalicylic acid) - **Chronic inflammatory demyelinating polyradiculoneuropathy** (**CIDP**) - **Multifocal motor neuropathy** (**MMN**).	23/07/2007	Instituto Grifols S.A.
FOTIVDA	tivozanib hydrochloride monohydrate	First line treatment of adult patients with advanced **renal cell carcinoma** (**RCC**) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.	24/08/2017	EUSA Pharma (Netherlands) B.V.
GLIOLAN	5-aminole-vulinic acid hydrochloride	In adult patients for visualisation of malignant tissue during surgery for **malignant glioma** (World Health Organization grade III and IV).	07/09/2007	medac Gesellschaft für klinische Spezialpräparate mbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
GLIVEC	imatinib mesilate	Treatment of adult and paediatric patients with newly diagnosed **Philadelphia chromosome** (bcr-abl) **positive** (**Ph+**) **chronic myeloid leukaemia** (**CML**) for whom bone marrow transplantation is not considered as the first line of treatment. Treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. Treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive **acute lymphoblastic leukaemia** (**Ph+ ALL**) integrated with chemotherapy. Treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy. Treatment of adult patients with **myelodysplastic / myeloproliferative diseases** (**MDS/MPD**) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements. Treatment of adult patients with advanced **hypereosinophilic syndrome** (**HES**) and/or **chronic eosinophilic leukaemia** (**CEL**) with FIP1L1-PDGFRα rearrangement. The effect of Glivec on the outcome of bone marrow transplantation has not been determined. Treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant **gastrointestinal stromal tumours** (**GIST**). Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive **GIST**. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. Treatment of adult patients with unresectable **dermatofibrosarcoma protuberans** (**DFSP**) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.	07/11/2001	Novartis Europharm Ltd
GONAL-F	follitropin alpha	Stimulation of spermatogenesis in men who have **congenital** or **acquired hypogonadotrophic hypogonadism** with concomitant human Chorionic Gonadotrophin (hCG) therapy.	20/10/1995	Merck Europe B.V.
GRASTOFIL	filgrastim	In adult or children patients with **severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil** count (ANC) of ≤ 0.5 x 10^9/L, and a history of severe or recurrent infections, long term administration of Grastofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	18/10/2013	Accord Healthcare S.L.U.
HALAVEN	eribulin	Treatment of adult patients with unresectable **liposarcoma** who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.	17/03/2011	Eisai GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HALIMATOZ	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). HYRIMOZ can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	25/07/2018	Sandoz GmbH
HEFIYA	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). HEFIYA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	25/07/2018	Sandoz GmbH
HELIXATE NEXGEN	octocog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.	04/08/2000	Bayer AG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HEMLIBRA	emicizumab	Indicated for routine prophylaxis of bleeding episodes in patients with **:** - **haemophilia A** (**congenital factor VIII deficiency**) with factor VIII inhibitors. - severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors. Hemlibra can be used in all age groups.	23/02/2018	Roche Registration GmbH
HERCEPTIN	trastuzumab	In combination with capecitabine or 5-fluorouraciland cisplatin, treatment of patients with HER2-positive metastatic **adenocarcinoma of the stomach or gastroesophageal junction** who have not received prior anticancer treatment for their metastatic disease. Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC3+ result. Accurate and validated assay methods should be used.	28/08/2000	Roche Registration GmbH
HIZENTRA	human normal immunoglobulin (scig)	Replacement therapy in adults, children and adolescents (0-18 years) in: − **Primary immunodeficiency syndromes** with impaired antibody production. − Hypogammaglobulinaemia and recurrent bacterial infections in patients with **chronic lymphocytic leukaemia** (**CLL**), in whom prophylactic antibiotics have failed or are contra-indicated. − Hypogammaglobulinaemia and recurrent infections in **multiple myeloma** (**MM**) patients. − Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT). Immunomodulatory therapy in adults, children and adolescents (0-18 years): - treatment of patients with **chronic inflammatory demyelinating polyneuropathy** (**CIDP**) as maintenance therapy after stabilization with IVIg.	14/04/2011	CSL Behring GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HULIO	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). HULIO can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	16/09/2018	Mylan S.A.S.
HUMIRA	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. It has not been studied in children aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	08/09/2003	AbbVie Deutschland GmbH & Co. KG
HYCAMTIN	topotecan	As monotherapy, treatment of: -patients with **metastatic carcinoma of the ovary** after failure of first-line or subsequent therapy. - patients with **relapsed small cell lung cancer** (**SCLC**) for whom retreatment with the first-line regimen is not considered appropriate.	12/11/1996	Novartis Europharm Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HYQVIA	human normal immunoglobulin	Replacement therapy in adults (≥ 18 years) in primary immunodeficiency syndromes such as: - **congenital agammaglobulinaemia** and **hypogammaglobulinaemia** - **common variable immunodeficiency** - **severe combined immunodeficiency** - **IgG subclass deficiencies** with recurrent infections. Replacement therapy in adults (≥ 18 years) in **myeloma or chronic lymphocytic leukaemia** with severe secondary hypogammaglobulinaemia and recurrent infections.	16/05/2013	Baxalta Innovations GmbH
HYRIMOZ	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). HYRIMOZ can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	25/07/2018	Sandoz GmbH
IBLIAS	octocog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**). Iblias can be used for all age groups.	18/02/2016	Bayer AG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
IDACIO	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). IDACIO can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids,in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	02/04/2019	Fresenius Kabi Deutschland GmbH
ILARIS	canakinumab	Treatment of **Cryopyrin-Associated Periodic Syndromes** (**CAPS**) in adults, adolescents and children aged 2 years and older with body weight of 7,5 kg or above, including: - **Muckle-Wells Syndrome** (**MWS**), - **Neonatal-Onset Multisystem Inflammatory Disease** (**NOMID**) / **Chronic Infantile Neurological**, **Cutaneous**, **Articular Syndrome** (**CINCA**), - Severe forms of **Familial Cold Autoinflammatory Syndrome** (**FCAS**) / **Familial Cold Urticaria** (**FCU**) presenting with signs and symptoms beyond cold- induced urticarial skin rash. Treatment of active Still's disease including **Adult-Onset Still's Disease** (**AOSD**) and **Systemic Juvenile Idiopathic Arthritis** (**SJIA**) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.	23/10/2009	Novartis Europharm Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
IMATINIB TEVA	imatinib	Treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) **chronic myeloid leukaemia** (**CML**) for whom bone marrow transplantation is not considered as the first line of treatment. Treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. Treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive **acute lymphoblastic leukaemia** (**Ph+ ALL**) integrated with chemotherapy. Treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy. Treatment of adult patients with **myelodysplastic/myeloproliferative diseases** (**MDS/MPD**) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. Treatment of adult patients with advanced **hypereosinophilic syndrome** (**HES**) and/or **chronic eosinophilic leukaemia** (**CEL**) with FIP1L1-PDGFRα rearrangement. The effect of imatinib on the outcome of bone marrow transplantation has not been determined. Treatment of adult patients with unresectable **dermatofibrosarcoma protuberans** (**DFSP**) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.	08/01/2013	Teva B.V.
IMRALDI	adalimumab	In combination with methotrexate indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.	24/08/2017	Samsung Bioepis NL B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
INCRELEX	mecasermin	For the long-term treatment of **growth failure** in children and adolescents from 2 to 18 years with **severe primary insulin-like growth factor-1 deficiency** (**Primary IGFD**). Severe Primary IGFD is defined by: - height standard deviation score ≤ -3.0 and - basal IGF-1 levels below the 2.5th percentile for age and gender and - GH sufficiency - exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test.	03/08/2007	Ipsen Pharma
INLYTA	axitinib	Treatment of adult patients with advanced **renal cell carcinoma** (**RCC**) after failure of prior treatment with sunitinib or a cytokine.	03/09/2012	Pfizer Europe MA EEIG
INOMAX	nitric oxide	In conjunction with ventilatory support and other appropriate active substances: - for the treatment of newborn infants ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echo cardiographic evidence of **pulmonary hypertension**, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. - as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.	01/08/2001	Linde Healthcare AB
INOVELON	rufinamide	Adjunctive therapy in the treatment of seizures associated with **Lennox-Gastaut syndrome** in patients aged 1 year and older.	16/01/2007	Eisai GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
INTRONA	interferon alpha-2b	Treatment of patients with **hairy cell leukaemia**. As Monotherapy for the treatment of adult patients with **Philadelphia chromosome or bcr/abl translocation positive chronic myelogenous leukaemia**. Clinical experience indicates that a haematological and cytogenetic major/minor response is obtainable in the majority of patients treated. A major cytogenetic response is defined by < 34 % Ph+ leukaemic cells in the bone marrow, whereas a minor response is > 34 %, but < 90 % Ph+ cells in the marrow. In combination with interferon alfa-2b and cytarabine (Ara-C) during the first 12 months of treatment it has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy. As maintenance therapy in patients with **multiple myeloma** who have achieved objective remission (more than 50 % reduction in myeloma protein) following initial induction chemotherapy. Current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated. Treatment of high tumour burden **follicular lymphoma** as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen. High tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°C for more than 8 days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia. Treatment of **carcinoid tumours** with lymph node or liver metastases and with "**carcinoid syndrome**".	09/03/2000	Merck Sharp & Dohme B.V.
NEW IVOZALL	clofarabine	Treatment of **acute lymphoblastic leukaemia** (**ALL**) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.	14/11/2019	ORPHELIA Pharma SAS
IXIARO	japanese encephalitis vaccine (inacti-vated, adsorbed)	Active immunisation against **Japanese encephalitis** in adults, adolescents, children and infants aged 2 months and older. IXIARO should be considered for use in individuals at risk of exposure through travel or in the course of their occupation	31/03/2009	Valneva Austria GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
JAKAVI	ruxolitinib	Treatment of disease-related splenomegaly or symptoms in adult patients with **primary myelofibrosis** (also known as chronic idiopathic myelofibrosis), **post-polycythaemia-vera myelofibrosis** or **post-essential-thrombocythaemia myelofibrosis.** Treatment of adult patients with **polycythaemia vera** who are resistant to or intolerant of hydroxyurea.	23/08/2012	Novartis Europharm Ltd
JINARC	tolvaptan	Indicated to slow the progression of cyst development and renal insufficiency of **autosomal dominant polycystic kidney disease** (**ADPKD**) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease.	27/05/2015	Otsuka Pharmaceutical Netherlands B.V.
JIVI	damoctocog alfa pegol	Treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with **haemophilia A** (**congenital factor VIII deficiency**).	22/11/2018	Bayer AG
KEPPRA	levetiracetam	As monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed **epilepsy**. As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy; in the treatment of myoclonic seizures in adults and adolescents from12 years of age with **Juvenile Myoclonic Epilepsy** Treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with **Idiopathic Generalised Epilepsy**.	29/09/2000	UCB Pharma SA
KEYTRUDA	pembrolizumab	As monotherapy for the treatment of adult patients with relapsed or refractory **classical Hodgkin lymphoma** (**cHL**) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV. As monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of metastatic or unresectable recurrent **head and neck squamous cell carcinoma** (**HNSCC**) in adults whose tumours express PD-L1 with a CPS ≥ 1. As monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumours express PD-L1 with a ≥ 50% TPS and progressing on or after platinum containing chemotherapy. In combination with axitinib, for the first-line treatment of advanced **renal cell carcinoma** (**RCC**) in adults.	17/07/2015	Merck Sharp & Dohme B.V.
KIGABEQ	vigabatrin	In infants and children from 1 month to less than 7 years of age for: -Treatment in monotherapy of **infantile spasms** (**West's syndrome**).	19/09/2018	ORPHELIA Pharma SAS

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
KINERET	anakinra	Treatment in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above of **Cryopyrin-Associated Periodic Syndromes** (**CAPS**), including:- **Neonatal-Onset Multisystem Inflammatory Disease** (**NOMID**) / **Chronic Infantile Neurological, Cutaneous, Articular Syndrome** (**CINCA**),- **Muckle-Wells Syndrome** (**MWS**),- **Familial Cold Autoinflammatory Syndrome** (**FCAS**). In adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of **Still's disease**, including **Systemic Juvenile Idiopathic** **Arthritis** (**SJIA**) and **Adult-** **Onset Still's Disease** (**AOSD**), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).	08/03/2002	Swedish Orphan Biovitrum AB (publ)
KIOVIG	human normal immunoglobulin	Replacement therapy in adults, and children and adolescents (0-18 years) in: - **Primary immunodeficiency syndromes** with impaired antibody production, - **Hypogammaglobulinaemia** and recurrent bacterial infections in patients with **chronic lymphocytic leukaemia**, in whom prophylactic antibiotics have failed - Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase **multiple myeloma** patients who have failed to respond to pneumococcal immunisation, - Hypogammaglobulinaemia in patients after allogeneic **haematopoietic stem cell transplantation** (HSCT). - Congenital AIDS and recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: - **Primary immune thrombocytopenia** (**ITP**), in patients at high risk of bleeding or prior to surgery to correct the platelet count - **Guillain Barré syndrome** - **Kawasaki disease** - **Multifocal Motor Neuropathy** (**MMN**).	19/01/2006	Takeda Manufacturing Austria AG
KISPLYX	lenvatinib	In combination with everolimus for the treatment of adult patients with advanced **renal cell carcinoma** (**RCC**) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	25/08/2016	Eisai GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
KOGENATE BAYER	octocog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease. This product is indicated for adults, adolescents and children of all ages.	04/08/2000	Bayer AG
KOVALTRY	octocog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**). Kovaltry can be used for all age groups.	18/02/2016	Bayer AG
KROMEYA	adalimumab	In combination with methotrexate is indicated for the treatment of active **polyarticular juvenile idiopathic arthritis**, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). KROMEYA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Treatment of active **enthesitis-related arthritis** in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Treatment of **non-infectious intermediate**, **posterior** and **panuveitis** in adult patients who have had an inadequate response to corticosteroids,in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Treatment of paediatric chronic **non-infectious anterior uveitis** in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	02/04/2019	Fresenius Kabi Deutschland GmbH
LENALIDOMIDE ACCORD	lenalidomide	As monotherapy for the maintenance treatment of adult patients with newly diagnosed **multiple myeloma** who have undergone autologous stem cell transplantation. As combination therapy for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.	19/09/2018	Accord Healthcare S.L.U.
LENVIMA	lenvatinib	As monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, **differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma** (**DTC**) refractory to radioactive iodine (RAI). As monotherapy for the treatment of adult patients with advanced or unresectable **hepatocellular carcinoma** (**HCC**) who have received no prior systemic therapy.	28/05/2015	Eisai GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
LITAK	cladribine	Treatment of **hairy cell leukaemia**.	14/04/2004	Lipomed GmbH
LOJUXTA	lomitapide	Adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with **homozygous familial hypercholesterolaemia (HoFH).**Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.	31/07/2013	Amryt Pharmaceuticals DAC
LYNPARZA	olaparib	**Lynparza capsules:** As monotherapy for the maintenance treatment of adult patients with **platinum-sensitive relapsed BRCA-mutated** (germline and/or somatic) **high grade serous epithelial ovarian**, **fallopian tube**, or **primary peritoneal cancer** who are in response (complete response or partial response) to platinum-based chemotherapy. **Lynparza tablets:** As monotherapy for the: * maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. * maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.	16/12/2014	AstraZeneca AB
LYSODREN	mitotane	Symptomatic treatment of advanced (unresectable, metastatic or relapsed) **adrenal cortical carcinoma**. The effect of Lysodren on non functional adrenal cortical carcinoma is not established.	28/04/2004	HRA Pharma Rare Diseases

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
MABTHERA	rituximab	**Non-Hodgkin's lymphoma** (**NHL**) - Treatment of previously untreated patients with stage III-IV **follicular lymphoma** in combination with chemotherapy. - As maintenance therapy, the treatment of follicular lymphoma patients responding to induction therapy. - In monotherapy, treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. - Treatment of patients with CD20 positive **diffuse large B cell non- Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with chemotherapy, treatment of patients with previously untreated and relapsed/ refractory **chronic lymphocytic leukaemia**. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy. **Granulomatosis with polyangiitis and Microscopic polyangiitis** - In combination with glucocorticoids, it is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and Microscopic polyangiitis (MPA). **Pemphigus vulgaris** Treatment of patients with moderate to severe pemphigus vulgaris (PV).	02/06/1998	Roche Registration GmbH
MEPACT	mifamurtide	In children, adolescents and young adults for the treatment of high-grade resectable non-metastatic **osteosarcoma** after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.	06/03/2009	Takeda France SAS
MIGLUSTAT DIPHARMA	miglustat	Indicated for the oral treatment of adult patients with mild to moderate **type 1 Gaucher disease**. Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.	18/02/2019	Dipharma B.V.
MIGLUSTAT GEN ORPH	miglustat	Oral treatment of adult patients with mild to moderate **type 1 Gaucher disease**. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.	10/11/2017	Gen.Orph

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
MVASI	bevacizumab	In combination with interferon alfa-2a indicated for first-line treatment of adult patients with advanced and/or metastatic **renal cell cancer**. In combination with carboplatin and paclitaxel indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) **epithelial ovarian**, **fallopian tube**, or **primary peritoneal cancer**. In combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.	15/01/2018	Amgen Europe B.V.
MYOZYME	alglucosidase alpha	Long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of **Pompe disease** (**acid α-glucosidase deficiency**). Myozyme is indicated in adults and paediatric patients of all ages	29/03/2006	Genzyme Europe B.V.
MYSILDECARD	sildenafil	Treatment of adult patients with **pulmonary arterial hypertension** classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.	15/09/2016	MYLAN S.A.S.
NAGLAZYME	galsulfase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of **Mucopolysaccharidosis VI** (**MPS VI**; **N-acetylgalactosamine 4-sulfatase deficiency**; **Maroteaux-Lamy syndrome**) A key issue is to treat children aged <5 years suffering from a severe form of the disease, even though children <5 years were not included in the pivotal phase 3 study. Limited data are available in patients < 1 year of age.	24/01/2006	BioMarin International Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
NEOFORDEX	dexamethasone	Indicated in adults for the treatment of symptomatic **multiple myeloma** in combination with other medicinal products.	16/03/2016	Laboratoires CTRS
NEXAVAR	sorafenib tosylate	Treatment of **hepatocellular carcinoma**. Treatment of patients with advanced **renal cell carcinoma** who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.	19/07/2006	Bayer AG
NITISINONE MDK (previously NITISINONE MENDELIKABS)	nitisinone	Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of **hereditary tyrosinemia type 1** (**HT 1**) in combination with dietary restriction of tyrosine and phenylalanine.	24/08/2017	MendeliKABS Europe Ltd
NITYR	nitisinone	Treatment of adult and paediatric patients with confirmed diagnosis of **hereditary tyrosinemia type 1** (**HT-1**) in combination with dietary restriction of tyrosine and phenylalanine.	26/07/2018	Cycle Pharmaceuticals (Europe) Ltd
NIVESTIM	filgrastim	In patients, children or adults, with **severe congenital, cyclic,** or **idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/l, and a history of severe or recurrent infections.	08/06/2010	Pfizer Europe MA EEIG
NONAFACT	human coagulation factor IX	Treatment and prophylaxis of bleeding in patients with **haemophilia B (congenital factor IX deficiency).**	03/07/2001	Sanquin Plasma Products B.V.
NORDIMET	methotrexate	Treatment of polyarthritic forms of severe, active **juvenile idiopathic arthritis** (**JIA**), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate.	18/08/2016	Nordic Group B.V.
NOVOEIGHT	turoctocog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia A (congenital factor VIII deficiency).** NovoEight can be used for all age groups.	13/11/2013	Novo Nordisk A/S
NOVOSEVEN	eptacog alpha (activated)	Treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups : -patients with **congenital haemophilia** with inhibitors to coagulation factors **VIII** or **IX**> 5 BU -patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration -patients with **acquired haemophilia** -patients with **congenital FVII deficiency**; -patients with **Glanzmann's thrombasthenia** with past or present refractoriness to platelet transfusions, or where platelets are not readily available.	23/02/1996	Novo Nordisk A/S
NOVOTHIRTEEN	catridecacog	Long term prophylactic treatment of bleeding in in adult and paediatric patients with **congenital factor XIII A-subunit deficiency**	03/09/2012	Novo Nordisk A/S

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
NOXAFIL	posaconazole	Treatment of the fungal infections in adults: - Invasive **aspergillosis** in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products - **Fusariosis** in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B. - **Chromoblastomycosis** and **mycetoma** in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - **Coccidioidomycosis** in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Prophylaxis of invasive fungal infections in : - Patients receiving remission-induction chemotherapy for **acute myelogenous leukemia** (**AML**) or **myelodysplastic syndromes** (**MDS**) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections - **Hematopoietic stem cell transplant** (**HSCT**) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	25/10/2005	Merck Sharp & Dohme B.V.
NPLATE	romiplostim	Indicated for chronic **immune** (**idiopathic**) **thrombocytopenic purpura** (**ITP**) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)	04/02/2009	Amgen Europe B.V.
NUWIQ	simoctocog alfa	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (congenital factor VIII deficiency). Nuwiq can be used for all age groups.	21/07/2014	Octapharma AB
OBIZUR	susoctocog alfa	Treatment of bleeding episodes in patients with **acquired haemophilia** caused by antibodies to Factor VIII.	11/11/2015	Baxalta Innovations GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
OMNITROPE	somatropin	Infants, children and adolescents: - Growth disturbance due to insufficient secretion of growth hormone (**growth hormone deficiency, GHD**). - Growth disturbance associated with **Turner syndrome**. - Growth disturbance associated with chronic renal insufficiency. - Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted height SDS < -1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by 4 years of age or later. - **Prader-Willi syndrome** (**PWS**), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults - Replacement therapy in adults with pronounced **growth hormone deficiency**. - *Adult onset:* Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency. - *Childhood onset:* Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a hypothalamic-pituitary disease or insult, an insulin-like growth factor-I (IGF-I) SDS < -2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD. All other patients will require IGF-I assay and one growth hormone stimulation test.	12/04/2006	Sandoz GmbH
ONCASPAR	pegaspargase	Indicated as a component of antineoplastic combination therapy in **acute lymphoblastic leukaemia** (**ALL**) in paediatric patients from birth to 18 years, and adult patients.	14/01/2016	Les Laboratoires Servier

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
OPDIVO	nivolumab	As monotherapy indicated for the treatment of advanced **renal cell carcinoma** after prior therapy in adults. In combination with ipilimumab for the first -line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma. As monotherapy for the treatment of adult patients with relapsed or refractory **classical Hodgkin lymphoma** after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. As monotherapy for the treatment of **squamous cell cancer of the head and neck** in adults progressing on or after platinum-based therapy.	19/06/2015	Bristol-Myers Squibb Pharma EEIG
ORENCIA	abatacept	In combination with methotrexate, for the treatment of moderate to severe active **polyarticular juvenile idiopathic arthritis** (**JIA**) in paediatric patients 6 years of age and older who have had an inadequate response to DMARD therapy. Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.	21/05/2007	Bristol-Myers SquibbPharma EEIG
ORFADIN	nitisinone	Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of **hereditary tyrosinemia type 1** (**HT-1**) in combination with dietary restriction of tyrosine and phenylalanine.	21/02/2005	Swedish Orphan Biovitrum AB
ORKAMBI	lumacaftor / ivacaftor	Orkambi tablets are indicated for the treatment of **cystic fibrosis** (**CF**) in patients aged 6 years and older who are homozygous for the *F508de*l mutation in the *CFTR* gene Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 2 years and older who are homozygous for the *F508del* mutation in the *CFTR* gene.	19/11/2015	Vertex Pharmaceuticals (Ireland) Limited
OVALEAP	follitropin alpha	Indicated for the stimulation of spermatogenesis in adult men who have **congenital** or **acquired hypogonadotropic hypogonadism** with concomitant human chorionic gonadotropin (hCG) therapy.	27/09/2013	Theramex Ireland Limited
OZURDEX	dexamethasone	For the treatment of adult patients with inflammation of the posterior segment of the eye presenting as **non-infectious uveitis.**	27/07/2010	Allergan Pharmaceuticals Ireland
PANRETIN	alitretinoin	Topical treatment of cutaneous lesions in patients with AIDS-related **Kaposi's sarcoma** (**KS**): - when lesions are not ulcerated or lymphoedematous, and -treatment of visceral KS is not required, and -when lesions are not responding to systemic antiretroviral therapy, and -radiotherapy or chemotherapy are not appropriate.	11/10/2000	Eisai GmbH
PEDEA	ibuprofen	Treatment of a haemodynamically significant **patent ductus arteriosus** in preterm newborn infants less than 34 weeks of gestational age.	29/07/2004	Recordati Rare Diseases

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
PEMETREXED ACCORD	pemetrexed disodium hemipentahydrate	In combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	18/01/2016	Accord Healthcare S.L.U.
PEMETREXED FRESENIUS KABI	pemetrexed diacid	In combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	22/07/2016	Fresenius Kabi Deutschland GmbH
PEMETREXED HOSPIRA	pemetrexed disodium hemipentahydrate	In combination with cisplatin indicated for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma.**	20/11/2015	Pfizer Europe MA EEIG
PEMETREXED Krka	pemetrexed disodium	In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	22/05/2018	Krka d. d., Novo mesto
PEMETREXED LILLY	pemetrexed disodium	In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	14/09/2015	Eli Lilly Nederland B.V.
PEMETREXED MEDAC	pemetrexed disodium hemipentahydrate	In combination with cisplatin indicated for the treatment of chemotherapy naïve patients with unresectable malignant **pleural mesothelioma**.	27/11/2015	medac Gesellschaft für klinische Spezialpräparate mbH
PEMETREXED SANDOZ	pemetrexed disodium hemipentahydrate	In combination with cisplatin for the treatment of chemotherapy naive patients with unresectable malignant **pleural mesothelioma**.	18/09/2015	Sandoz GmbH
PEYONA (previously NYMUSA)	caffeine citrate	Treatment of **primary apnea of premature newborns**.	02/07/2009	Chiesi Farmaceutici SpA
PIXUVRI	pixantrone dimaleate	As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive **Non-Hodgkin B-cell Lymphomas** (**NHL**). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.	10/05/2012	Les laboratoires Servier
PRIALT	ziconotide	Treatment of severe, **chronic pain in patients who require intrathecal (IT) analgesia**.	21/02/2005	RIEMSER Pharma GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
PRIVIGEN	human normal immunoglobulin (IVIg)	Replacement therapy in adults, and children and adolescents (0-18 years) in: - **Primary immunodeficiency** (**PID**) syndromes with impaired antibody production - Hypogammaglobulinaemia and recurrent bacterial infections in patients with **chronic lymphocytic leukaemia**, in whom prophylactic antibiotics have failed. - Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase **multiple myeloma** patients who have failed to respond to pneumococcal immunisation. - Hypogammaglobulinaemia in patients after **allogeneic haematopoietic stem cell transplantation** (**HSCT**). - **Congenital AIDS** with recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: - **Primary immune thrombocytopenia** (**ITP**), in patients at high risk of bleeding or prior to surgery to correct the platelet count. - **Guillain-Barré syndrome**. - **Kawasaki disease**. - **Chronic inflammatory demyelinating polyneuropathy** (**CIDP**). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.	25/04/2008	CSL Behring GmbH
PUREGON	follitropin beta	Indicated in adult males with deficient spermatogenesis due to **hypogonadotrophic hypogonadism**.	03/05/1996	Merck Sharp & Dohme B.V.
QUINSAIR	levofloxacin	Management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in adult patients with **cystic fibrosis**	26/03/2015	Chiesi Farmaceutici S.p.A.
RAPAMUNE	sirolimus	Treatment of patients with sporadic **lymphangioleiomyomatosis** with moderate lung disease or declining lung function. (Indication extension)	12/03/2001	Pfizer Europe MA EEIG
RATIOGRASTIM	filgrastim	In patients, children or adults, with **severe congenital, cyclic,** or **idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/l, and a history of severe or recurrent infections.	15/09/2008	Ratiopharm GmbH
REFACTO AF	moroctocog alpha	Treatment and prophylaxis of bleeding in patients with **haemophilia A** (**congenital factor VIII deficiency**) in adults and children of all ages, including newborns. ReFacto AF is appropriate for use in adults and children of all ages, including newborns. ReFacto AF does not contain von Willebrand factor, and hence is not indicated in von Willebrand's disease.	13/04/1999	Pfizer Europe MA EEIG
REFIXIA	nonacog beta pegol	Treatment and prophylaxis of bleeding in patients 12 years and above with **haemophilia B** (congenital factor IX deficiency).	02/06/2017	Novo Nordisk A/S

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
REPATHA	evolocumab	Indicated in adults and adolescents aged 12 years and over with **homozygous familial hypercholesterolaemia** in combination with other lipid-lowering therapies. The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.	17/07/2015	Amgen Europe B.V.
REPLAGAL	agalsidase alfa	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of **Fabry disease** (**alpha- galactosidase A deficiency**)	03/08/2001	Shire Human Genetic Therapies AB
RESPREEZA	human alpha1-proteinase inhibitor	For maintenance treatment, to slow the progression of emphysema in adults with documented severe **alpha1-proteinase inhibitor deficiency** (e.g.genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g.lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.	20/08/2015	CSL Behring GmbH
REVATIO	sildenafil citrate	Treatment of adult patients with **pulmonary arterial hypertension** classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.	28/10/2005	Pfizer Europe MA EEIG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
REVLIMID	lenalidomide	As monotherapy for the maintenance treatment of adult patients with newly diagnosed **multiple myeloma** who have undergone autologous stem cell transplantation. As combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Treatment in combination with dexamethasone of multiple myeloma in adult patients who have received at least one prior therapy. Treatment of patients with transfusion-dependent anaemia due to low-or intermediate-1-risk **myelodysplastic syndromes** associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Treatment of adult patients with relapsed or refractory **mantle cell lymphoma**. In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated **follicular lymphoma**.	14/06/2007	Celgene Europe B.V.
REVOLADE	eltrombopag	Indicated for **chronic immune (idiopathic) thrombocytopenic purpura** (**ITP**) patients aged 1 year and above who are refractory to other treatments. Indicated in adult patients with **acquired severe aplastic anaemia** (**SAA**) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.	11/03/2010	Novartis Europharm Ltd
RILUTEK	riluzole	To extend life or the time to mechanical ventilation for patients with **amyotrophic lateral sclerosis** (**ALS**). Clinical trials have demonstrated that RILUTEK extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free. There is no evidence that RILUTEK exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. RILUTEK has not been shown to be effective in the late stages of ALS. Safety and efficacy of RILUTEK has only been studied in ALS. Therefore, RILUTEK should not be used in patients with any other form of motor neurone disease.	10/06/1996	Sanofi Mature IP

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
RITEMVIA	rituximab	Treatment of previously untreated patients with stage III, IV **follicular lymphoma** in combination with chemotherapy. As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy. As monotherapy for the treatment of patients with stage III, IV follicular lymphoma who are chemo resistant or are in their second or subsequent relapse after chemotherapy. Treatment of patients with CD20 positive **diffuse large B cell non Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active **granulomatosis with polyangiitis** (**Wegener's**) (**GPA**) and **microscopic polyangiitis** (**MPA**).	13/07/2017	Celltrion Healthcare Hungary Kft
RIXATHON	rituximab	Treatment of previously untreated patients with stage III-IV **follicular lymphoma** in combination with chemotherapy. As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy. As monotherapy for the treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. For the treatment of patients with CD20 positive **diffuse large B cell non Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory **chronic lymphocytic leukaemia**. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy. In combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active **granulomatosis with polyangiitis** (**Wegener's**) (**GPA**) and **microscopic polyangiitis** (**MPA**).	15/06/2017	Sandoz GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
RIXIMYO	rituximab	Treatment of previously untreated patients with stage III-IV **follicular lymphoma** in combination with chemotherapy. As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy. As monotherapy for the treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. For the treatment of patients with CD20 positive **diffuse large B cell non Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active **granulomatosis with polyangiitis** (**Wegener's**) (**GPA**) and **microscopic polyangiitis** (**MPA**).	15/06/2017	Sandoz GmbH
RIXUBIS	nonacog gamma	Treatment and prophylaxis of bleeding in patients with **haemophilia B** (**congenital factor IX deficiency**). RIXUBIS is indicated in patients of all age groups.	19/12/2014	Baxalta Innovations GmbH
ROACTEMRA	tocilizumab	RoActemra 20 mg/ml concentrate for solution for infusion: Treatment of active **systemic juvenile idiopathic arthritis** (**sJIA**) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX. In combination with methotrexate (MTX) it is indicated for the treatment of **juvenile idiopathic polyarthritis** (**pJIA**; **rheumatoid factor positive or negative** and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra 162 mg solution for injection in pre-filled syringe : Treatment of **Giant Cell Arteritis** (**GCA**) in adult patients.	16/01/2009	Roche Registration GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
RUBRACA	rucaparib	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed **high-grade epithelial ovarian**, **fallopian tube**, or **primary peritoneal cancer** who are in response (complete or partial) to platinum-based chemotherapy. As monotherapy for the treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.	24/05/2018	Clovis Oncology Ireland Limited
RUCONEST	conestat alfa	Treatment of acute angioedema attacks in adults and adolescents with **hereditary angioedema** (**HAE**) due to **C1 esterase inhibitor deficiency.**	28/10/2010	Pharming Group N.V.
SAVENE	dexrazoxane	Treatment of **anthracycline extravasation** in adults.	28/07/2006	Clinigen Healthcare B.V.
SIKLOS	hydroxycarbamide	Prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic **sickle cell syndrome.**	29/06/2007	Addmedica
SIMPONI	golimumab	In combination with methotrexate (MTX) for the treatment of **polyarticular juvenile idiopathic arthritis** in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.	01/10/2009	Janssen Biologics B.V.
SLENYTO	melatonin	Treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or **Smith-Magenis syndrome**, where sleep hygiene measures have been insufficient.	19/09/2018	RAD Neurim Pharmaceuticals EEC SARL.
SOLIRIS	eculizumab	Treatment of adults and children with **Paroxysmal nocturnal haemoglobinuria** (**PNH**). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.	20/06/2007	Alexion Europe SAS
SOMAVERT	pegvisomant	Treatment of adult patients with **acromegaly** who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.	13/11/2002	Pfizer Europe MA EEIG
SPECTRILA	asparaginase	Indicated as a component of antineoplastic combination therapy for the treatment of **acute lymphoblastic leukaemia** (**ALL**) in paediatric patients from birth to 18 years and adults.	14/01/2016	Medac Gesellschaft fuer klinische Spezialpraeparate mbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
SPRYCEL	dasatinib	Treatment of adult patients with: - newly diagnosed **Philadelphia chromosome positive** (**Ph+**) **chronic myelogenous leukaemia** (**CML**) in the chronic phase. - chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. - **Ph+ acute lymphoblastic leukaemia** (**ALL**) and lymphoid blast CML with resistance or intolerance to prior therapy. Treatment of paediatric patients with: -newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. -newly diagnosed Ph+ ALL in combination with chemotherapy.	20/11/2006	Bristol-Myers SquibbPharma EEIG
STAYVEER	bosentan monohydrate	Treatment of **pulmonary arterial hypertension** (**PAH**) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in: • **Primary** (idiopathic and heritable) **pulmonary arterial hypertension** • **Pulmonary arterial hypertension secondary to scleroderma** without significant interstitial pulmonary disease • **Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology**. Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II. Indicated to reduce the number of new digital ulcers in patients with **systemic sclerosis** and ongoing digital ulcer disease	24/06/2013	Janssen-Cilag International NV
SUTENT	sunitinib	Treatment of unresectable and/or metastatic **malignant gastrointestinal stromal tumour** (**GIST**) in adults after failure of imatinib treatment due to resistance or intolerance. Treatment of **advanced/metastatic renal cell carcinoma** (**MRCC**) in adults. Treatment of unresectable or metastatic, well-differentiated **pancreatic neuroendocrine tumours** (**pNET**) with disease progression in adults. Experience with SUTENT as first-line treatment is limited	19/07/2006	Pfizer Europe MA EEIG
TALMANCO (previouslyTADALAFIL GENERICS)	tadalafil	Indicated in adults for the treatment of **pulmonary arterial hypertension** (**PAH**) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	09/01/2017	MYLAN S.A.S

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TARCEVA	erlotinib	In combination with gemcitabine, for the treatment of patients with metastatic **pancreatic cancer**. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival advantage could be shown for patients with locally advanced disease.	19/09/2005	Roche Registration GmbH
TARGRETIN	bexarotene	Treatment of skin manifestations of advanced stage **cutaneous T-cell lymphoma** (**CTCL**) patients refractory to at least one systemic treatment.	29/03/2001	Eisai GmbH
TASIGNA	nilotinib	Treatment of adult and paediatric patients with newly diagnosed **Philadelphia chromosome positive chronic myelogenous leukaemia** (**CML**) in the chronic phase. Adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available. Paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.	19/11/2007	Novartis Europharm Ltd
TAXOTERE	docetaxel	In combination with cisplatin and 5-fluorouracil for the induction treatment of patients with locally advanced **squamous cell carcinoma of the head and neck.**	27/11/1995	Sanofi Mature IP
TEMODAL	temozolomide	Treatment of adult patients with newly-diagnosed **glioblastoma multiforme** concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. Treatment of children from the age of three years, adolescents and adult patients with **malignant glioma**, such as glioblastoma multiforme or **anaplastic astrocytoma**, showing recurrence or progression after standard therapy.	26/01/1999	Merck Sharp & Dohme B.V.
TEVAGRASTIM	filgrastim	In patients, children or adults, with **severe congenital, cyclic,** or **idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/l, and a history of severe or recurrent infections.	15/09/2008	Teva GmbH
TEYSUNO	tegafur/gimeracil/ oteracil	In adults for the treatment of advanced **gastric cancer** when given in combination with cisplatin.	14/03/2011	Nordic Group BV
THALIDOMIDE CELGENE (previously THALIDOMIDE PHARMION)	thalidomide	In combination with melphalan and prednisone as first line treatment of patients with untreated **multiple myeloma**, aged ≥ 65 years or ineligible for high dose chemotherapy. Thalidomide Celgene is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme	16/04/2008	Celgene Europe B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
THYROGEN	thyrotropin alfa	For use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and **well-differentiated thyroid cancer** in post-thyroidectomy patients maintained on hormone suppression therapy (THST). Low-risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. For pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnantsin patients who have undergone a near-total ortotal thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distantmetastatic thyroid cancer.	09/03/2000	Genzyme Europe B.V.
TOBRAMYCIN PARI	tobramycin	Indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with **cystic fibrosis** (**CF**)	18/02/2019	Pari Pharma GmbH
TORISEL	Temsirolimus	- First-line treatment of adult patients with advanced **renal cell carcinoma** (**RCC**) who have at least three of six prognostic risk factors. - Treatment of adult patients with relapsed and/ or refractory **mantle cell lymphoma** (**MCL**).	19/11/2007	Pfizer Europe MA EEIG
TRACLEER	bosentan monohydrate	Treatment of **pulmonary arterial hypertension** (**PAH**) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in: - **primary (idiopathic and heritable) PAH**, - **PAH secondary to scleroderma** without significant interstitial pulmonary disease, - **PAH associated with congenital systemic-to- pulmonary shunts** and **Eisenmenger's physiology**. Some improvements have also been shown in patients with PAH WHO functional class II. To reduce the number of new digital ulcers in patients with **systemic sclerosis** and ongoing digital ulcer disease.	15/05/2002	Janssen-Cilag International NV
TRECONDI	treosulfan	In combination with fludarabine is indicated as part of conditioning treatment prior to **allogeneic haematopoietic stem cell transplantation** (**alloHSCT**) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.	20/06/2019	MEDAC GMBH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TRISENOX	arsenic trioxide	Indicated for induction of remission, and consolidation in adult patients with: • Newly diagnosed low-to-intermediate risk **acute promyelocytic leukaemia** (**APL**) (white blood cell count, ≤ 10 x 103/µl) in combination with all-trans-retinoic acid (ATRA) • Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.	05/03/2002	Teva B.V.
TRUXIMA	rituximab	Treatment of previously untreated patients with stage III-IV **follicular lymphoma** in combination with chemotherapy. Truxima maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. Truxima monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy. Treatment of patients with CD20 positive **diffuse large B cell non-Hodgkin's lymphoma** in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory **Chronic lymphocytic leukaemia** (**CLL**) . Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Truxima or patients refractory to previous Truxima plus chemotherapy. In combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active **granulomatosis with polyangiitis** (**Wegener's**) (**GPA**) and **microscopic polyangiitis** (**MPA**).	17/02/2017	Celltrion Healthcare Hungary Kft.
UCEDANE	carglumic acid	Treatment of hyperammonaemia due to **N-acetylglutamate synthase primary deficiency**.	23/06/2017	Eurocept International BV
ULTOMIRIS	ravulizumab	Treatment of adult patients with **paroxysmal nocturnal haemoglobinuria** (**PNH**): - in patients with haemolysis with clinical symptom(s) indicative of high disease activity - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.	02/07/2019	Alexion Europe SAS

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
UPTRAVI	selexipag	Long-term treatment of **pulmonary arterial hypertension** (**PAH**) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.	12/05/2016	Janssen-Cilag International NV
VEDROP	tocofersolan	Indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with **congenital chronic cholestasis** or **hereditary chronic cholestasis**, from birth (full term newborns) up to 18 years of age.	24/07/2009	Recordati Rare Diseases
VELCADE	bortezomib	As monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive **multiple myeloma** who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. In combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated **mantle cell lymphoma** who are unsuitable for haematopoietic stem cell transplantation.	26/04/2004	Janssen-Cilag International N.V.
VENCLYXTO	venetoclax	In combination with rituximab for the treatment of adult patients with **chronic lymphocytic leukaemia** (**CLL**) who have received at least one prior therapy. As monotherapy for the treatment of CLL: - in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or - in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor.	05/12/2016	AbbVie Deutschland GmbH & Co. KG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VENTAVIS	iloprost	Treatment of patients with **primary pulmonary hypertension**, classified as NYHA functional class III, to improve exercise capacity and symptoms.	16/09/2003	Bayer AG
VEYVONDI	vonicog alfa	In adults (age 18 and older) with **von Willebrand Disease** (**VWD**), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the: - Treatment of haemorrhage and surgical bleeding - Prevention of surgical bleeding. VEYVONDI should not be used in the treatment of Haemophilia A	30/08/2018	Baxalta Innovations GmbH
VFEND	voriconazole	In adults and children aged 2 years and above as follows: - treatment of **invasive aspergillosis**. - treatment of **serious fungal infections** caused by ***Scedosporium spp.*** and ***Fusarium spp.*** Vfend should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.	19/03/2002	Pfizer Europe MA EEIG
VIDAZA	azacitidine	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: - intermediate-2 and high-risk **myelodysplastic syndromes** (**MDS**) according to the International Prognostic Scoring System (IPSS), - **chronic myelomonocytic leukaemia** (**CMML**) with 10-29% marrow blasts without myeloproliferative disorder, - **acute myeloid leukaemia** (**AML**) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification. Treatment of adult patients aged 65 years or older who are not eligible for HSCT with **AML** with >30% marrow blasts according to the WHO classification.	17/12/2008	Celgene Europe B.V.
VOLIBRIS	ambrisentan	Treatment of **pulmonary arterial hypertension** (**PAH**) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in **idiopathic PAH** (**IPAH**) and in PAH associated with connective tissue disease.	21/04/2008	GlaxoSmithKline (Ireland) Limited
VONCENTO	human coagulation factor viii/ von willebrand factor	Treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with **von Willebrand disease** (**VWD**), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Prophylaxis and treatment of bleeding in patients with **haemophilia A** (**congenital FVIII deficiency**).	12/08/2013	CSL Behring GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VORICONAZOLE HIKMA (PREVIOUSLY VORICONAZOLE HOSPIRA)	voriconazole	In adults and children aged 2 years and above as follows: - treatment of **invasive aspergillosis**. - treatment of serious fungal infections caused by ***Scedosporium spp.*** and ***Fusarium spp.*** Voriconazole should be administered primarily to patients with progressive, possibly life – threatening infections.	27/05/2015	Hikma Farmaceutica (Portugal) S.A.
VOTRIENT	pazopanib	In adults for the first-line treatment of advanced **renal cell carcinoma** (**RCC**) and for patients who have received prior cytokine therapy for advanced disease. For the treatment of adult patients with selective subtypes of advanced **soft-tissue sarcoma** (**STS**) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)-adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.	14/06/2010	Novartis Europharm Ltd
WILZIN	zinc acetate dihydrate	Treatment of **Wilson's disease.**	13/10/2004	Recordati Rare Diseases
XAGRID	anagrelide hydrochloride	Reduction of elevated platelet counts in at-risk **essential-thrombocythaemia** (**ET**) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk ET is defined by one or more of the following features: - > 60 years of age or - a platelet count > 1000 x 10^9/l or - a history of thrombo-haemorrhagic events.	16/11/2004	Shire Pharmaceuticals Ireland Limited
XELODA	capecitabine	First-line treatment of advanced **gastric cancer** in combination with a platinum-based regimen	02/02/2001	Roche Registration GmbH
XROMI	hydroxycarbamide	Indicated for the prevention of vaso-occlusive complications of **Sickle Cell Disease** in patients over 2 years of age.	01/07/2019	Nova Laboratories Ireland Limited
XYREM	sodium oxybate	Treatment of **narcolepsy with cataplexy** in adult patients.	13/10/2005	UCB Pharma S.A.
YARGESA	miglustat	For the oral treatment of adult patients with mild to moderate **type 1 Gaucher disease**. Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable	22/03/2017	Piramal Critical Care B.V.
YERVOY	ipilimumab	In combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.	12/07/2011	Bristol-Myers Squibb Pharma EEIG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
YONDELIS	trabectedin	Treatment of adult patients with advanced **soft tissue sarcoma**, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on **liposarcoma** and **leiomyosarcoma** patients. In combination with pegylated liposomal doxorubicin (PLD), treatment of patients with relapsed platinum-sensitive **ovarian cancer**.	17/09/2007	Pharma MarS.A.
ZARZIO	filgrastim	In children and adults with **severe congenital, cyclic, or idiopathic neutropenia** with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	06/02/2009	Sandoz GmbH
ZAVESCA	miglustat	Treatment of adult patients with mild to moderate **type 1 Gaucher disease**. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Treatment of progressive neurological manifestations in adult patients and paediatric patients with **Niemann-Pick type C disease.**	21/11/2002	Janssen-Cilag International NV
ZEVALIN	ibritumomab tiuxetan	Consolidation therapy after remission induction in previously untreated patients with **follicular lymphoma.** Treatment of adult patients with rituximab relapsed or refractory CD20+ follicular **B-cell non-Hodgkin's lymphoma** (**NHL**).	16/01/2004	Spectrum Pharmaceuticals B.V.
ZUTECTRA	human hepatitis B immunoglobulin	Prevention of **hepatitis B virus** (**HBV**) **re-infection** in HBV-DNA negative patients over 6 months **after liver transplantation for hepatitis B induced liver failure**. Zutectra is indicated in adults only. The concomitant use of adequate virostatic agents should be considered, if appropriate, as standard of hepatitis B re-infection prophylaxis.	30/11/2009	Biotest Pharma GmbH
ZYDELIG	idelalisib	In combination with rituximab, treatment of adult patients with **chronic lymphocytic leukaemia** (**CLL**): - who have received at least one prior therapy, or - as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. As monotherapy, treatment of adult patients with **follicular lymphoma (FL)** that is refractory to two prior lines of treatment.	18/09/2014	Gilead Sciences Ireland UC

Clasificación por fecha de la AC en orden decreciente

2019
AMBRISENTAN MYLAN
ARSENIC TRIOXIDE ACCORD
AZACITIDINE CELGENE
BESREMI
BORTEZOMIB FRESENIUS KABI
CUFENCE
DEFERASIROX MYLAN
ERVEBO
ESPEROCT
IDACIO
IVOZALL
KROMEYA
MIGLUSTAT DIPHARMA
TOBRAMYCIN PARI
TRECONDI
ULTOMIRIS
XROMI
2018
ADYNOVI
ALKINDI
ANAGRELIDE MYLAN
CARMUSTINE OBVIUS
DEFERIPRONE
DENGVAXIA
HALIMATOZ
HEFIYA
HEMLIBRA
HULIO
HYRIMOZ
JIVI
KIGABEQ
LENALIDOMIDE ACCORD
MVASI
NITYR
PEMETREXED Krka
RUBRACA
SLENYTO
VEYVONDI
2017
AFSTYLA
AMGEVITA
BAVENCIO
BLITZIMA
CUPRIOR
ELMIRON
ERELZI
FOTIVDA
IMRALDI
MIGLUSTAT GEN ORPH
NITISINONE MDK
REFIXIA
RITEMVIA
RIXATHON
RIXIMYO
TALMANCO
TRUXIMA
UCEDANE
YARGESA
2016
ARMISARTE
BORTEZOMIB HOSPIRA
BORTEZOMIB SUN
CABOMETYX
EMPLICITI
IBLIAS
KISPLYX
KOVALTRY
MYSILDECARD
NEOFORDEX
NORDIMET
ONCASPAR
PEMETREXED ACCORD
PEMETREXED FRESENIUS KABI
SPECTRILA
UPTRAVI
VENCLYXTO
2015
BORTEZOMIB ACCORD
ELOCTA
JINARC
KEYTRUDA
LENVIMA
OBIZUR
OPDIVO
ORKAMBI
PEMETREXED HOSPIRA
PEMETREXED LILLY
PEMETREXED MEDAC
PEMETREXED SANDOZ
QUINSAIR
REPATHA
RESPREEZA
VORICONAZOLE HIKMA
2014
ACCOFIL
BEMFOLA
CYRAMZA
LYNPARZA
NUWIQ
RIXUBIS
ZYDELIG
2013
BOSULIF
ERIVEDGE
GRASTOFIL
HYQVIA
IMATINIB TEVA
LOJUXTA
NOVOEIGHT
OVALEAP
STAYVEER
VONCENTO
2012
CAPRELSA
COLOBREATHE
INLYTA
JAKAVI
NOVOTHIRTEEN
PIXUVRI
2011
BUCCOLAM
CINRYZE
EURARTESIM
HALAVEN
HIZENTRA
TEYSUNO
YERVOY
2010
NIVESTIM
OZURDEX
REVOLADE
RUCONEST
VOTRIENT
2009
AFINITOR
CAYSTON
FILGRASTIM HEXAL
ILARIS
IXIARO
MEPACT
NPLATE
PEYONA
ROACTEMRA
SIMPONI
VEDROP
ZARZIO
ZUTECTRA
2008
ABRAXANE
ADCIRCA
CEPLENE
PRIVIGEN
RATIOGRASTIM
TEVAGRASTIM
THALIDOMIDE CELGENE
VIDAZA
VOLIBRIS
2007
ABSAMEAD
ATRIANCE
BINOCRIT
CYSTADANE
DIACOMIT
ELAPRASE
EPOETIN ALFA HEXAL
FLEBOGAMMA DIF
GLIOLAN
INCRELEX
INOVELON
ORENCIA
REVLIMID
SIKLOS
SOLIRIS
TASIGNA
TORISEL
YONDELIS
2006
KIOVIG
EVOLTRA
EXJADE
NEXAVAR
OMNITROPE
MYOZYME
NAGLAZYME
SAVENE
SPRYCEL
SUTENT
2005
AVASTIN
NOXAFIL
ORFADIN
PRIALT
REVATIO
TARCEVA
XYREM
2004
ADVATE
ALIMTA
DUKORAL
ERBITUX
LITAK
LYSODREN
PEDEA
VELCADE
WILZIN
XAGRID
ZEVALIN
2003
ALDURAZYME
BUSILVEX
CARBAGLU
HUMIRA
VENTAVIS
2002
KINERET
SOMAVERT
TRACLEER
TRISENOX
VFEND
ZAVESCA
2001
CANCIDAS
CEPROTIN
FABRAZYME
GLIVEC
INOMAX
NONAFACT
RAPAMUNE
REPLAGAL
TARGRETIN
XELODA
2000
ENBREL
HELIXATE NEXGEN
HERCEPTIN
INTRONA
KEPPRA
KOGENATE BAYER
PANRETIN
THYROGEN
1999
AMMONAPS
FERRIPROX
REFACTO AF
TEMODAL
1998
MABTHERA
1997
BENEFIX
CEREZYME
CYSTAGON
1996
CAELYX
HYCAMTIN
NOVOSEVEN
PUREGON
RILUTEK
1995
GONAL-F
TAXOTERE


Número de medicamentos huérfanos en Europa con autorización de comercialización europea, sin designación huérfana en Europa por fecha de la AC
2
5
3
1
4
8
10
6
5
11
7
10
18
9
13
5
7
6
10
7
16
17
19
20
17
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Clasificación por categoría ATC

A- ALIMENTARY TRACT AND METABOLISM
ALDURAZYME
AMMONAPS
CARBAGLU
CEREZYME
CUFENCE
CUPRIOR
CYSTADANE
CYSTAGON
ELAPRASE
FABRAZYME
MIGLUSTAT DIPHARMA
MIGLUSTAT GEN ORPH
MYOZYME
NAGLAZYME
NITISINONE MDK
NITYR
ORFADIN
REPLAGAL
UCEDANE
VEDROP
WILZIN
YARGESA
ZAVESCA
B- BLOOD AND BLOOD FORMING ORGANS
ABSEAMED
ADVATE
ADYNOVI
AFSTYLA
BENEFIX
BINOCRIT
CEPROTIN
CINRYZE
ELOCTA
EPOETIN ALFA HEXAL
ESPEROCT
HELIXATE NEXGEN
HEMLIBRA
IBLIAS
JIVI
KOGENATE BAYER
KOVALTRY
NONAFACT
NOVOEIGHT
NOVOSEVEN
NOVOTHIRTEEN
NPLATE
NUWIQ
OBIZUR
REFACTO AF
REFIXIA
RESPREEZA
REVOLADE
RIXUBIS
RUCONEST
UPTRAVI
VENTAVIS
VEYVONDI
VONCENTO
C- CARDIOVASCULAR SYSTEM
AMBRISENTAN MYLAN
JINARC
LOJUXTA
PEDEA
REPATHA
STAYVEER
TRACLEER
VOLIBRIS
G- GENITO URINARY SYSTEM AND SEX HORMONES
ADCIRCA
BEMFOLA
ELMIRON
GONAL-F
MYSILDECARD
OVALEAP
PUREGON
REVATIO
TALMANCO
H- SYSTEMIC HORMONAL PREPARATIONS, EXCL, SEX HORMONES AND INSULINS
ALKINDI
INCRELEX
NEOFORDEX
OMNITROPE
SOMAVERT
THYROGEN
J- GENERAL ANTIINFECTIVES FOR SYSTEMIC USE
CANCIDAS
CAYSTON
DENGVAXIA
DUKORAL
ERVEBO
FLEBOGAMMA DIF
HIZENTRA
HYQVIA
IXIARO
KIOVIG
NOXAFIL
PRIVIGEN
QUINSAIR
TOBRAMYCIN PARI
VFEND
VORICONAZOLE HIKMA
ZUTECTRA
L- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ABRAXANE
ACCOFIL
AFINITOR
ALIMTA
AMGEVITA
ANAGRELIDE MYLAN
ARMISARTE
ARSENIC TRIOXIDE ACCORD
ATRIANCE
AVASTIN
AZACITIDINE CELGENE
BAVENCIO
BESREMI
BLITZIMA
BORTEZOMIB ACCORD
BORTEZOMIB FRESENIUS KABI
BORTEZOMIB HOSPIRA
BORTEZOMIB SUN
BOSULIF
BUSILVEX
CABOMETYX
CAELYX
CAPRELSA
CARMUSTINE OBVIUS
CEPLENE
CYRAMZA
EMPLICITI
ENBREL
ERBITUX
ERELZI
ERIVEDGE
EVOLTRA
FILGRASTIM HEXAL
FOTIVDA
GLIOLAN
GLIVEC
GRASTOFIL
HALAVEN
HALIMATOZ
HEFIYA
HERCEPTIN
HULIO
HUMIRA
HYCAMTIN
HYRIMOZ
IDACIO
ILARIS
IMATINIB TEVA
IMRALDI
INLYTA
INTRONA
IVOZALL
JAKAVI
KEYTRUDA
KINERET
KISPLYX
KROMEYA
LENALIDOMIDE ACCORD
LENVIMA
LITAK
LYNPARZA
LYSODREN
MABTHERA
MEPACT
MVASI
NEXAVAR
NIVESTIM
NORDIMET
ONCASPAR
OPDIVO
ORENCIA
PANRETIN
PEMETREXED ACCORD
PEMETREXED FRESENIUS KABI
PEMETREXED HOSPIRA
PEMETREXED Krka
PEMETREXED LILLY
PEMETREXED MEDAC
PEMETREXED SANDOZ
PIXUVRI
RAPAMUNE
RATIOGRASTIM
REVLIMID
RITEMVIA
RIXATHON
RIXIMYO
ROACTEMRA
RUBRACA
SIKLOS
SIMPONI
SOLIRIS
SPECTRILA
SPRYCEL
SUTENT
TARCEVA
TARGRETIN
TASIGNA
TAXOTERE

TEMODAL
TEVAGRASTIM
TEYSUNO
THALIDOMIDE CELGENE
TORISEL
TRECONDI
TRISENOX
TRUXIMA
ULTOMIRIS
VELCADE
VENCLYXTO
VIDAZA

VOTRIENT
XAGRID
XELODA
XROMI
YERVOY
YONDELIS
ZARZIO
ZYDELIG
N- NERVOUS SYSTEM
BUCCOLAM
DIACOMIT
INOVELON
KEPPRA

KIGABEQ
PEYONA
PRIALT
RILUTEK
SLENYTO
XYREM
P- ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
EURARTESIM
R- RESPIRATORY SYSTEM
COLOBREATHE

INOMAX
ORKAMBI
S- SENSORY ORGANS
OZURDEX
V- VARIOUS
DEFERASIROX MYLAN
DEFERIPRONE
EXJADE
FERRIPROX
SAVENE
ZEVALIN

Número de medicamentos huérfanos en Europa con autorización de comercialización europea, sin previa designación huérfana en Europa por categoría ATC



Clasificación por el titular de la AC

ABBVIE DEUTSCHLAND GMBH & CO. KG
HUMIRA
VENCLYXTO
ACCORD HEALTHCARE S.L.U.
ACCOFIL
ARSENIC TRIOXIDE ACCORD
BORTEZOMIB ACCORD
GRASTOFIL
LENALIDOMIDE ACCORD
PEMETREXED ACCORD
ACTAVIS GROUP PTC EHF
ARMISARTE
ADDMEDICA
SIKLOS
ALEXION EUROPE SAS
SOLIRIS
ULTOMIRIS
ALFASIGMA S.P.A
EURARTESIM
ALLERGAN PHARMACEUTICALS IRELAND
OZURDEX
AMGEN EUROPE BV
AMGEVITA
MVASI
NPLATE
REPATHA
AMRYT PHARMACEUTICALS DAC
LOJUXTA
AOP ORPHAN PHARMACEUTICALS AG
BESREMI
APOTEX B.V.
FERRIPROX
ASTRAZENECA AB
LYNPARZA
BAXALTA INNOVATIONS GMBH
ADYNOVI
HYQVIA
OBIZUR
RIXUBIS
VEYVONDI
BAXTER AG
ADVATE
CEPROTIN
BAYER AG
HELIXATE NEXGEN
IBLIAS
JIVI
KOGENATE BAYER
KOVALTRY
NEXAVAR
VENTAVIS
BENE- ARZNEIMITTEL GMBH
ELMIRON
BIOCODEX
DIACOMIT
BIOMARIN INTERNATIONAL Limited
NAGLAZYME
BIOTEST PHARMA GMBH
ZUTECTRA
BRISTOL-MYERS SQUIBB PHARMA EEIG
EMPLICITI
OPDIVO
ORENCIA
SPRYCEL
YERVOY
CELGENE EUROPE B.V.
ABRAXANE
AZACITIDINE CELGENE
REVLIMID
THALIDOMIDE CELGENE
VIDAZA
CELLTRION HEALTHCARE HUNGARY KFT.
BLITZIMA
RITEMVIA
TRUXIMA
CHIESI FARMACEUTICI S.P.A.
PEYONA
QUINSAIR
CLINIGEN HEALTHCARE B.V.
SAVENE
CLOVIS ONCOLOGY IRELAND LIMITED
RUBRACA
CSL BEHRING GMBH
AFSTYLA
HIZENTRA
PRIVIGEN
RESPREEZA
VONCENTO
CYCLE PHARMACEUTICALS (EUROPE) LTD
NITYR
DIPHARMA B.V.
MIGLUSTAT DIPHARMA
DIURNAL EUROPE B.V.
ALKINDI
EISAI GmbH
HALAVEN
INOVELON
KISPLYX
LENVIMA
PANRETIN
TARGRETIN
ELI LILLY NEDERLAND B.V.
ADCIRCA
ALIMTA
CYRAMZA
PEMETREXED LILLY
EUROCEPT INTERNATIONAL BV
UCEDANE
EUSA PHARMA (NETHERLANDS) B.V.
FOTIVDA
FRESENIUS KABI DEUTSCHLAND GMBH
BORTEZOMIB FRESENIUS KABI
IDACIO
KROMEYA
PEMETREXED FRESENIUS KABI
GEDEON RICHTER PLC.
BEMFOLA
GEN.ORPH
MIGLUSTAT GEN ORPH
GENZYME EUROPE B.V.
ALDURAZYME
CAPRELSA
CEREZYME
EVOLTRA
FABRAZYME
MYOZYME
THYROGEN
GILEAD SCIENCES IRELAND UC
CAYSTON
ZYDELIG
GLAXOSMITHKLINE (IRELAND) LIMITED
VOLIBRIS
GMP-ORPHAN SA
CUPRIOR
HEXAL AG
EPOETIN ALFA HEXAL
FILGRASTIM HEXAL
HIKMA FARMACEUTICA (PORTUGAL), S.A.
VORICONAZOLE HIKMA
HRA PHARMA RARE DISEASES
LYSODREN
IMMEDICA PHARMA AB
AMMONAPS
INSTITUTO GRIFOLS S.A.
FLEBOGAMMA DIF
IPSEN PHARMA
CABOMETYX
INCRELEX
JANSSEN BIOLOGICS B.V.
SIMPONI
JANSSEN-CILAG INTERNATIONAL NV
CAELYX
STAYVEER
TRACLEER
UPTRAVI
VELCADE
ZAVESCA
KRKA D. D., NOVO MESTO
PEMETREXED Krka
LABORATOIRES CTRS
NEOFORDEX
LES LABORATOIRES SERVIER
ONCASPAR
PIXUVRI
LINDE HEALTHCARE AB
INOMAX
LIPOMED GMBH
DEFERIPRONE LIPOMED
LITAK
MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH
GLIOLAN
PEMETREXED MEDAC
SPECTRILA
TRECONDI
MEDICE ARZNEIMITTEL PÜTTER GMBH & CO KG
ABSEAMED
MENDELIKABS EUROPE LTD
NITISINONE MDK
MERCK EUROPE B.V.
BAVENCIO
ERBITUX
GONAL-F
MERCK SHARP & DOHME B.V.
CANCIDAS
ERVEBO
INTRONA
KEYTRUDA
NOXAFIL
PUREGON
TEMODAL
MYLAN SAS
AMBRISENTAN MYLAN
ANAGRELIDE MYLAN
DEFERASIROX MYLAN
HULIO
MYSILDECARD
TALMANCO
NORDIC GROUP BV
NORDIMET
TEYSUNO
NOVA LABORATORIES IRELAND LIMITED
XROMI
NOVARTIS EUROPHARM LTD
AFINITOR
ATRIANCE
EXJADE
GLIVEC
HYCAMTIN
ILARIS
JAKAVI
REVOLADE
TASIGNA
VOTRIENT
NOVENTIA PHARMA SRL
CEPLENE
NOVO NORDISK A/S
ESPEROCT
NOVOEIGHT
NOVOSEVEN
NOVOTHIRTEEN
REFIXIA
OBVIUS INVESTMENT B.V..
CARMUSTINE OBVIUS
OCTAPHARMA AB
NUWIQ

ORPHELIA PHARMA SAS
KIGABEQ
ORPHELIA PHARMA SAS
IVOZALL
OTSUKA PHARMACEUTICAL NETHERLANDS B.V.
JINARC
PARI PHARMA GMBH
TOBRAMYCIN PARI
PFIZER EUROPE MA EEIG
BENEFIX
BORTEZOMIB HOSPIRA
BOSULIF
ENBREL
INLYTA
NIVESTIM
PEMETREXED HOSPIRA
RAPAMUNE
REFACTO AF
REVATIO
SOMAVERT
SUTENT
TORISEL
VFEND
PHARMA MAR S.A.
YONDELIS
PHARMING GROUP N.V.
RUCONEST
PIERRE FABRE MÉDICAMENTS
BUSILVEX
PIRAMAL CRITICAL CARE B.V.
YARGESA

RAD NEURIM PHARMACEUTICALS EEC SARL
SLENYTO
RATIOPHARM GMBH
RATIOGRASTIM
RECORDATI RARE DISEASES
CARBAGLU
CYSTADANE
CYSTAGON
PEDEA
VEDROP
WILZIN
RIEMSER PHARMA GMBH
PRIALT
ROCHE REGISTRATION GMBH
AVASTIN
ERIVEDGE
HEMLIBRA
HERCEPTIN
MABTHERA
ROACTEMRA
TARCEVA
XELODA
SAMSUNG BIOEPIS NL B.V.
IMRALDI
SANDOZ GMBH
BINOCRIT
ERELZI
HALIMATOZ
HEFIYA
HYRIMOZ

OMNITROPE
PEMETREXED SANDOZ
RIXATHON
RIXIMYO
ZARZIO
SANOFI MATURE IP
RILUTEK
TAXOTERE
SANOFI PASTEUR
DENGVAXIA
SANQUIN PLASMA PRODUCTS B.V.
NONAFACT
SHIRE HUMAN GENETIC THERAPIES AB
ELAPRASE
REPLAGAL
SHIRE PHARMACEUTICALS IRELAND LIMITED
XAGRID
SHIRE SERVICES BVBA
BUCCOLAM
CINRYZE
SPECTRUM PHARMACEUTICALS B.V.
ZEVALIN
SUN Pharmaceutical Industries (Europe) B.V.
BORTEZOMIB SUN
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
ELOCTA
KINERET

SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB
ORFADIN
TAKEDA FRANCE SAS
MEPACT
TAKEDA MANUFACTURING AUSTRIA AG
KIOVIG
TEVA BV
COLOBREATHE
IMATINIB TEVA
TRISENOX
TEVA GMBH
TEVAGRASTIM
THERAMEX IRELAND LIMITED
OVALEAP
UCB PHARMA SA
KEPPRA
XYREM
UNIVAR BV
CUFENCE
VALNEVA AUSTRIA GMBH
IXIARO
VALNEVA SWEDEN AB
DUKORAL
VERTEX PHARMACEUTICALS (IRELAND) LIMITED
ORKAMBI

Por favor, tenga en cuenta que todos los datos presentados en este informe están disponibles para su descarga en Orphadata

Redactoras : Ana Rath & Valérie Salamon ● Fotografía : M. Depardieu/Inserm

La forma adecuada par citar este documento es la siguiente :
« Listados de medicamentos para enfermedades raras en Europa », Informes Periódicos de Orphanet, Serie *Medicamentos Huérfanos*, enero 2020

,

Los informes de Orphanet forman parte de la Direct Grant N°831390, que ha recibido financiación del Programa de Salud de la Unión Europea (2014-2020).

El contenido de los Informes de Orphanet refleja el punto de vista del autor, siendo éste el único responsable; en ningún supuesto se puede considerar que refleja la opinión de la Comisión uropea, la de la Agencia Ejecutiva de Consumidores, Salud, Agricultura y Alimentación o la de ningún otro órgano de la Unión Europea. La Comisión Europea y la Agencia no asumen ninguna responsabilidad derivada del uso que se pueda dar a la información que contienen.